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Polymers can be designed to interface with biological entities, including biological 
molecules, cells, and tissues, and to modulate their properties and behaviors. In this 
dissertation, biointerfacing polymers were used to overcome four key challenges in 
vaccine delivery, gene therapy, and cancer therapy. First, mucoadhesive wafers 
composed of binary polymer blends of carboxymethylcellulose and alginate were 
developed to preserve the activity and improve the sublingual delivery of protein 
vaccines. Second, polymer wafers composed of polyvinyl alcohol were developed to 
enhance polyplex-mediated gene transfection in vitro in the presence of serum. Third, a 
synthetic membranolytic polymer poly(6-amino-1-hexyl methacrylate) (PAHM) was 
used to disrupt cancer cell membrane, resulting in increased cellular uptake of 
doxorubicin and synergistic killing of cancer cells. Finally, PAHM was used to sensitize 
cancer cells to irreversible electroporation (IRE), leading to enhanced killing at electric 
field strengths lower than IRE alone. These studies have laid the foundation for future 
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Chapter 1 Introduction 
The first chapter of this thesis aims to provide a general background of polymer-
based drug delivery and to identify four challenges we will be addressing: (1) instability 
and insufficient mucosal permeation of sublingual protein vaccines; (2) inadequate 
transfection efficiency of polyplex-mediated gene delivery in the presence of serum; (3) 
cancer cell resistance to chemotherapy drugs; (4) inability of irreversible electroporation 
(IRE) to ablate large tumors. 
Another purpose of this chapter is to introduce the concept of “biointerfacing” 
polymers as a unifying theme to how we will overcome these challenges. We define 
biointerfacing polymers as materials that, due to their physicochemical properties, can 
interface with biological materials, including biomolecules (e.g., proteins, nucleic acids), 
cells, and tissues (Figure 1.1). Though this interfacing, these polymers can be used to 
overcome various challenges in vaccine delivery, gene therapy, and cancer therapy. 
Polymers can interface with proteins via hydrogen bonding to stabilize protein vaccines 
during storage and exposure to elevated temperatures. Through mucoadhesion, polymers 
can interface with sublingual epithelium to enhance permeation of protein vaccines into 
the mucosal tissue. Due to electrostatic interactions, polymers can interface with plasmid 
DNA to form and stabilize condensed polyplexes to improve transfection efficiency. 
Through electrostatic and hydrophobic interactions polymers can interface with cell 
membranes to induce membrane lysis, increase cellular uptake of chemotherapy drugs, 
and sensitize cells to IRE. 
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Figure 1.1 Polymers biointerfacing with biomolecules, cells, and tissues. 
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1.1 Polymer-based Drug Delivery Systems 
Polymers have a long history of use in delivering therapeutic agents to treat numerous 
medical conditions. Typically intended to provide some sort of spatiotemporal control, 
polymeric delivery systems are designed to deliver drugs to targeted anatomical sites 
within a therapeutic range for a desired duration. Polymers can also stabilize and provide 
safe passage for therapeutic agents through inhospitable regions. Many different types of 
polymeric delivery systems have been developed, including implants, hydrogels, 
colloidal carriers (e.g., micelles, microparticles, nanoparticles), polymer conjugates (e.g., 
polymer-drug conjugates, polymer-protein conjugates) [1]. Drugs can be encapsulated in 
hydrophobic, solvent-free polymer implants, which release drugs either through passive 
molecular diffusion, polymer erosion/degradation, or a combination of the two [2]. 
Hydrogels, composed of a crosslinked polymer network and large amount of water, can 
encapsulate and provided sustained release of hydrophilic drugs. In addition, hydrogels 
can have similar physical properties to tissues, which can offer excellent biocompatibility 
[3]. Colloidal carriers can have a high drug loading capacity (of both hydrophilic or 
hydrophobic drugs), can facilitate cellular uptake, and can be easily conjugated for active 
targeting [4]. Polymers can be conjugated to pharmaceutical agents to modify transport 
and circulation half-life characteristics, reduce immunogenicity, and provide passive and 
active targeting [1].  
The selection and design of a polymer can be difficult due to the vast diversity of 
characteristics required of a particular delivery system. Initially, polymers were intended 
to be inert carriers of a particular therapeutic; however, the need for polymers to be 
stimuli-responsive or exhibit bioactivity has been increasingly recognized [1]. Polymers 
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have been designed to respond to specific physical stimuli (such as temperature, 
ultrasound, light, and magnetic and electrical fields) or biochemical stimuli (such as pH, 
redox potential, and ionic strength) to trigger the release of a therapeutic agent [5]. 
Polymers have been designed to include passive or active targeting mechanisms to 
improve the distribution of a therapeutic agent within a particular tissue, cellular, or 
subcellular location [1]. Polymers with bioadhesive properties are especially useful when 
targeting mucosal tissues. Bioadhesive polymers can maintain sustained contact between 
a delivery system and mucosal epithelium, providing sufficient residence time for a 
therapeutic agent to permeate into the tissue [6]. Polymer conjugates have been widely 
used in anticancer agents due to the ability to passively target tumors via the enhanced 
permeation and retention (EPR) effect [7]. Once of the most commonly used polymers, 
polyethylene glycol (PEG), has been conjugated (i.e. PEGylation) to many FDA 
approved therapeutics [8]. The surface of nanoparticles, and other colloidal carriers, are 
often functionalized with ligands to actively target delivery to specific cell types [9]. 
Since many therapeutics are only effective if localized in a particular subcellular site 
(e.g., nucleus, cytosol, mitochondria), polymer carriers have also been designed to direct 
these agents to the appropriate site [10]. Polymers can also be designed to be biomimetic. 
Synthetic polymers designed to emulate the membranolytic abilities of host defense 
peptides have enormous potential as antimicrobial or anticancer agents [11].  
1.2 Instability and Insufficient Mucosal Permeation of Sublingual Protein Vaccines 
The large population of antigen presenting cells (APCs) in the sublingual mucosa 
make it a preferred site for antigen presentation (Figure 1.2) [12].  
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Figure 1.2 Antigen delivery and antigen presentation following sublingual vaccination. 
Sublingual mucosa contains many antigen presenting cells responsible for antigen uptake 
and induction of the adaptive immune response. Reprinted from Journal of Controlled 
Release, v. 190, H. Kraan, H. Vrieling, C. Czerkinsky, W. Jiskoot, G. Kersten, J.-P. 
Amorij, Buccal and sublingual vaccine delivery, p. 582, Copyright (2014), with 
permission from Elsevier. 
Many viral and bacterial pathogens primarily infect mucosal sites [13]. While most 
intramuscular (IM) and subcutaneous (SC) injections confer systemic immunity, they 
induce insufficient mucosal immunity [14]. Sublingual vaccines have been shown to be 
safe and highly effective in several animal models [12]. Sublingual delivery of a clade C 
HIV-1 envelope protein gp140 with alpha-galactosylceramide (αGalCer) and CpG-
oligodeoxynucleotide (CpG-ODN) as adjuvants has been shown to efficiently induce 
persistent humoral and cellular immune responses in the systemic and mucosal 
compartments of mice [15]. Genetic vaccination via the oral mucosa using cDNA for 
influenza A/WSN/33 (H1N1) hemagglutinin and the malaria Plasmodium berghei 
circumsporozoite protein (PbCSP) has generated antigen-specific CTL and IFN-γ 
production in hamsters [16]. Sublingual immunization with an adenovirus (Ad5)-based 
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vaccine for Ebola induced significant ZGP-specific Th1 and Th2 type responses that 
protected mice and guinea pigs from lethal challenge [17]. Sublingual delivery of an Ad5 
SIV-env/rev and SIV-gag vaccine in Rhesus Macaques generated SIV-specific immunity, 
including cellular responses, serum binding antibody, and mucosal secretory IgA [18]. 
Despite the success in preclinical studies, sublingual vaccines are rarely used in 
humans. One factor limiting the success of sublingual vaccines is the way in which they 
are delivered. Sublingual vaccines are usually delivered as liquid formulations [12]. 
While these formulations enable convenient and exact dosing, they provide insufficient 
adhesion and absorption through the sublingual epithelium [19]. As a result, the vaccines 
can be physically removed from the delivery site (e.g., swallowing, talking, eating, 
drinking, saliva wash-out), resulting in poor immunogenicity. This is particularly 
problematic for protein vaccines. Despite the long success of sublingual delivery of small 
molecule drugs [20], macromolecules have been much harder to deliver by this route. 
The sublingual epithelium serves as a permeability barrier to macromolecules [12]. 
A few mucoadhesive dosage forms have been studied for sublingual delivery of 
protein vaccines. Thiolated chitosan wafers have developed to improve the buccal 
delivery of insulin. While these wafers demonstrated a 1.7-fold increase of insulin 
delivery into EpiOral™ buccal tissue and sheep buccal membrane ex vivo, they have not 
shown efficacy in vivo [21]. Engineered liposomes (phospholipid-PEG liposomes coated 
with methylglycol chitosan) carrying CRX-601 (a synthetic toll like receptor-4 agonist), 
have been co-delivered sublingually with influenza antigens. In addition to being 
mucoadhesive, these liposomes may also act as permeation enhancers by opening 
epithelial tight junctions. Sublingual administration of this vaccine formulation generated 
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systemic immune responses and mucosal immune responses that were or comparable to 
or exceeded those generated IM administration [22]. While the stability of the liposomes 
was preliminarily tested, the stability of the influenza antigens was not. Combinations of 
Carbopol®, lactose, microcrystalline cellulose (MCC), hydroxyproply methylcellulose 
(HPMC), and ethylcellulose (EC) were used to formulate bilayer tablets (composed of a 
mucoadhesive layer and a controlled release layer) to investigate the effect of the model 
protein antigen (OVA) release rate on the immune response after sublingual 
immunization in mice. When compared to OVA in solution, fast protein release tablets 
(~5 min) elicited comparable antibody titers. However, the extended protein release (~24 
h) only induced low immune responses [23]. The immunized mice likely swallowed or 
spit out the extended release tablets before the full OVA dose was released. The issue of 
antigen stability was not addressed in this study. Bilayer films have also been 
investigated for buccal immunization in rabbits. Films composed of Noveon and Eudragit 
S-100 as the mucoadhesive layer and a pharmaceutical wax as the impermeable backing 
layer were loaded with β-galactosidase (β-gal) as a model protein antigen. Buccal 
immunization elicited serum antibody titers equivalent, if not greater, to SC injection. 
Plasmid DNA (CMV-β-gal) was also loaded into the bilayer films. Buccal immunization 
with plasmid DNA also elicited comparable antigen-specific IgG titers to SC protein 
injection; however, only the rabbits immunized with plasmid DNA via the buccal route 
demonstrated splenocyte proliferative immune responses [19]. While the stability of the 
released cargo was demonstrated, long-term stability was not investigated.  
A few formulations have been studied to improve delivery to oral mucosa while 
maintaining stability of biomacromolecules. Mucoadhesive electrospun patches have 
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recently been developed to deliver lysozyme to the oral mucosa for treating and 
preventing oral infections. Lysozyme was incorporated into 
poly(vinylpyrrolidone)/Eudragit RS100 nanofibers by electrospinning. Lysozyme 
released from the nanofibers maintained 96.1% of the enzyme activity and inhibited the 
growth of the oral bacterium Streptococcus ratti [24]. While the biological activity of 
lysozyme was preserved during preparation of the mucoadhesive patches, the issue of 
storage temperature or protection from heat denaturation was not investigated. Alginic 
acid nanoparticles, in combination with nicotinamide as a permeation enhancer, have 
been used to improve sublingual delivery of insulin. The mucoadhesive nanoparticles 
were shown to improve the pharmacological availability and bioavailability of insulin in 
a diabetic rat model. Albumin was added as a cryoprotectant to help preserve insulin. The 
chemical stability and structural integrity of insulin in nanoparticles was confirmed by 
HPLC and CD analysis [25]. While insulin stability was maintained after storage at 4ºC 
for 12 months, storage without refrigeration was not demonstrated. An oral cholera 
vaccine, Dukoral™ has been stabilized by sucrose during lyophilization; however, 
storage of the dry cholera vaccine formulation above 4ºC was not demonstrated [26]. An 
H5N1 flu virus vaccine has been stabilized by sublingual tablets composed of 
microcrystalline cellulose, crosslinked sodium carboxymethylcellulose, and mannitol. 
These tablets allow for storage at ambient temperatures, but the vaccines must be 
reconstituted prior to administration [27]. A commercial H1N1 flu virus vaccine 
(Fluarix®) has been incorporated into mucoadhesive tablets for delivery to the buccal 
mucosa of pigs. After three immunizations at 2 weeks interval, animals were challenged 
by inoculation of the A/H1N1 pandemic virus. While the buccal vaccine tablets showed 
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signs of priming the pig’s immune system, intramuscular injection of the commercial 
liquid vaccine generated superior immune responses. Antigen immunogenicity was 
shown to be preserved when tablets were stored at 4ºC or room temperature for up to 6 
months [28]. Antigen stability is likely due to the presence of the bulking agent mannitol 
and the lyoprotectant trehalose, not the mucoadhesive polymers. The flu vaccine was first 
freeze-dried with mannitol and trehalose before compression with magnesium stearate, 
fumed silica, and mucoadhesive polymer excipients (HPMC or milk protein concentrate). 
While these mucoadhesive dosages showed promise for sublingual vaccination, the 
protection of antigens from heat denaturation has not been addressed in these studies. 
Ideally, mucoadhesive formulation should protect protein antigens from inactivation due 
to lyophilization and heat exposure during storage and transport. 
1.3 Inadequate Transfection Efficiency of Polyplex-Mediated Gene Delivery in the 
Presence of Serum 
Gene therapy has the potential to treat or vaccinate against many diseases, including 
cancer, infectious diseases, and genetic disorders. Nucleic acids encoding for specific 
proteins from pathogens or mutated cancer cells can be delivered in DNA (or RNA) 
vaccines to instigate cell-mediated and humoral immune responses. Gene therapy can 
also deliver exogenous transgenes to replace or knockdown endogenous genes [29]. Gene 
delivery falls into two classes – viral and nonviral. Viral vectors have been genetically 
altered to prevent viral replication, reduce cytotoxicity, and allow incorporation of a 
therapeutic transgene. While these viral vectors can be very efficient, they have a limited 
gene carrying capacity, are unable to transfect nondividing cells, and can be difficult to 
mass-produce [30]. Moreover, immunogenicity and oncogenicity are significant safety 
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concerns that have limited their clinical applications [31]. Nonviral gene delivery 
involves the use of plasmid DNA either alone or, more commonly, complexed to 
synthetic carrier molecules. Nonviral systems address many of the issues associated with 
viral vectors, including flexibility in the transgene size, simplified manufacturing, and 
lower immunogenicity. However, nonviral systems are significantly less efficient than 
viral vectors [30]. 
The low efficiency of nonviral gene delivery is primarily due to the numerous barriers 
(Figure 1.3) between the site of administration and localization in the cell nucleus. DNA 
(and its delivery vehicle) are first susceptible to extracellular barriers, including 
enzymatic degradation by nucleases, complement-mediated clearance, and 
reticuloendothelial system recognition. Next, the DNA must cross the cell membrane. 
Endocytosis is the primary mechanism responsible for cellular uptake; however, DNA 
must escape from the endosomal compartments prior trafficking to lysosomes, where 
DNA is subject to intracellular degradation. Finally, DNA must be transported though the 




Figure 1.3 Barriers to polyplex-mediated gene delivery. Adapted with permission from 
Molecular Pharmaceutics, v.10, C.H. Jones, C.-K. Chen, A. Ravikrishnan, S. Rane, B.A. 
Pfeifer, Overcoming Nonviral Gene Delivery Barriers: Perspective and Future, p. 4082, 
Copyright (2013) American Chemical Society. 
Many synthetic carriers have been developed to overcome these barriers to gene 
delivery. One of the commonly used type of carrier are cationic polymers, which form 
complexes with anionic DNA via electrostatic interactions. These condensed sub-micron-
size particles are termed polyplexes [29]. Polyplexes can protect DNA from nuclease 
degradation and enhance cellular uptake, due to the attraction of the net-positively 
charged polyplexes to negatively charged cell membranes [30]. Many cationic polymers 
have been used to form polyplexes, including poly-L-lysine (PLL), polyamidoamine 
(PAMAM), and polyethyleneimine (PEI) [32]. PEI is the most commonly used polymer 
to form polyplexes for gene delivery [33]. The repeating amine structure not only allows 
PEI to form compact and tightly bound polyplexes to protect DNA from nuclease 
degradation and facilitate cellular uptake, but the numerous secondary and tertiary amines 
in branched PEI are thought to facilitate endosomal escape by the “proton sponge” 
mechanism. As the polyplex-containing endosome acidifies, the amines become 











































account for the increased ion influx, additional water also enters the vesicle. This results 
in osmotic swelling and eventual rupture, releasing the polyplexes into the cytosol [29]. 
Despite the improvement over naked DNA, polyplex-mediated gene delivery still 
struggles in vivo. A primary issue with polyplexes is their colloidal instability. 
Adsorption of serum albumin and other anionic proteins can cause polyplexes to 
aggregate, degrade, or unpackage, resulting in poor cellular uptake and ultimately low 
transfection efficiency [29]. Various strategies have been investigated to improve 
polyplex colloidal stability and transfection efficiency. Covalent attachment of PEG to 
polyplexes was hypothesized to provide a steric barrier against aggregation and reduce 
interaction with blood components. However, PEGylated polyplexes were actually less 
stable in blood. The PEGylated polyplexes were found to unpackage more easily, likely 
due to the presence of PEG trapped in the core of the polyplexes, weakening the 
electrostatic interactions holding them together [34]. Covalent attachment of polyvinyl 
alcohol (PVA) to PEI has also been explored. The PVA-PEI/DNA polyplexes displayed 
high in vitro transfection efficiency in the presence of serum. The transfection efficiency 
of PVA-PEI/DNA polyplexes were also examined in mice. Seven days after intravenous 
injection, gene expression was high in the spleen; however, transfection efficiency was 
lower in other major organs (lungs, heart, kidney, liver, brain) [35]. Succinylation of 
primary and secondary amines of PEI to produce zwitterion-like polyplexes has been 
shown to decrease aggregation and increase the in vitro transfection efficiency in the 
presence of serum. A balance between the advantages of succinylation with the required 
charge density to condense and protect DNA was discovered. Polyplexes with 9 – 25% of 
the amines modified by succinylation were found to be most effective. Transgene 
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expression was up to 51-fold greater than unmodified PEI/DNA in the presence of serum; 
however, these zwitterion-like polyplexes were not tested in vivo [36]. PEI-based 
polyplexes (and lipopolyplexes) have also been encapsulated into PVA microparticles. 
This nanoparticles-in-microparticle delivery system (NiMDS) was found to reduce 
cytotoxicity and enhance the transfection efficiency in the presence of serum in multiple 
cell lines [37]. The NiMDS was also spray dried into a powder and delivered to mice by 
an inhalation chamber. Approximately 1% of lung cells expressed the transgene after one 
administration; however, the transfection efficiency of the NiMDS was not tested in other 
organs [38]. Ideally, a polymeric delivery system should enhance the transfection 
efficiency of nonviral gene therapy and be capable of delivering genes to different 
tissues. 
1.4 Cancer Cell Resistance to Chemotherapy Drugs 
Cancer remains a leading cause of morbidity and mortality globally. An estimated 
13.1 million people will die due to cancer in 2030 [39]. Chemotherapy is a current 
standard of care for many types of cancer; however, resistance to chemotherapeutics 
plagues many treatment regimens [40]. Many classes of chemotherapy drugs have been 
developed, including taxanes, anthracyclines, epipodophyllotoxins, and antimetabolites. 
Despite the structural and functional differences of these drugs, most anticancer agents 
have intracellular targets [11]. Cancer cells that develop mechanisms to pump the drugs 
out of the cells or deactivate the drugs with certain intracellular pathways can become 
multidrug resistant (Figure 1.4) [41]. While dose escalation can theoretically increase 
intracellular drug concentration, it can also exacerbate resistance mechanisms and toxic 
side effects [42]. 
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Figure 1.4 Mechanisms leading to multidrug resistance in cancer cells. Mechanisms 
leading to multidrug resistance in cancer cells. Reprinted from Biomaterials, v. 252, J. 
Tan, J. Tay, J. Hedrick, Y.Y. Yang, Synthetic macromolecules as therapeutics that 
overcome resistance in cancer and microbial infection, p. 8, Copyright (2020), with 
permission from Elsevier. 
In addition to multidrug resistance, low accumulation in tumor tissue, poor aqueous 
solubility, short circulation half-life, and off-target toxicity have limited the efficacy of 
many chemotherapy drugs [40]. Because many chemotherapeutics target rapidly dividing 
cells they can also display toxicity against fast-dividing non-malignant cells, resulting in 
decreased blood cell production, digestive tract inflammation, and hair loss [43]. To 
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combat some of these issues, thousands of nanoparticle delivery systems have been 
developed, about a dozen of which have been FDA approved from clinical use [42]. 
Encapsulation of doxorubicin in liposomes (i.e. Lipodox®) results in the preferential 
accumulation in tumor tissue while limiting cardiotoxicity. The liposomes are unable to 
cross vasculature with tight capillary junctions (e.g., in myocardium) but can escape 
leaky tumor vasculature [39]. PEGylated-liposomal doxorubicin (i.e. Doxil®/Caelyx®) 
can also prolong the circulation half-life by reducing uptake by the reticuloendothelial 
system [44]. Despite the advantageous of these nanoparticle delivery systems, they rely 
on the intracellular action of the drug and are still susceptible to multidrug resistance 
mechanisms [43]. It may be more difficult for cancer cells to develop resistance to 
therapies that do not have intracellular targets [45], such as membranolytic polymers or 
irreversible electroporation. These membrane-targeting approaches could be used as 
monotherapies or combined with conventional chemotherapy for a potential synergistic 
effect. 
1.5 Inability of Irreversible Electroporation to Ablate Large Tumors 
Irreversible electroporation (IRE) involves the use of high-voltage short electrical 
pulses to create permanent pores within a cell membrane, leading to cell death by 
permanent membrane lysis or loss of homeostasis (Figure 1.5) [46]. IRE can be used as a 
focal therapy to ablate tumors, similar to cryoablation, radiofrequency ablation, or 
microwave ablation [47]. These thermal ablation modalities are minimally invasive 
treatment options for patients with tumors in various organs, including liver, lungs, and 
kidneys [48,49]. However, the reliance on heating or cooling to induce cell death carries 
the risk of damaging healthy tissues, such as blood vessels, bile ducts, and nerves [50]. 
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Additionally, the thermal energy can be dissipated by nearby blood flow, creating a heat 
sink (or cold sink) effect that limits the ability to ablate tumors that are adjacent to major 
blood vessels [47]. 
 
Figure 1.5 Schematic illustration of irreversible electroporation (IRE). IRE uses a series 
of high-voltage short electrical pulses to permanently disrupt cell membranes, leading to 
cell death. Reprinted from Radiology, v. 295, B. Geboers, H.J. Scheffer, P.M. Graybill, 
A.H. Ruarus, S. Nieuwenhuizen, R.S. Puijk, P.M. van den Tol, R. V. Davalos, B. 
Rubinsky, T.D. de Gruijl, D. Miklavčič, M.R. Meijerink, High-Voltage Electrical Pulses 
in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, 
Electrofusion, and Electroimmunotherapy, p. 254-272, Copyright (2020), with 
permission from Radiological Society of North America. 
In contrast IRE, a nonthermal therapy, can be used to ablate tumors near large blood 
vessels or vital structures, such as sensitive vasculature, bile ducts, urethra, or nerves 
[51]. Due to specificity for the cell membrane, IRE also spares the extracellular matrix, 
allowing for faster healing of healthy tissue while minimizing scarring [52]. IRE is 
currently used to treat tumors in the prostate, liver, pancreas, and kidneys [53,54] and 
may be efficacious for tumors in other organs, such as the lungs, breast, brain, and spinal 
cord [55,56].  
Despite the advantages of IRE, it is usually considered a “last resort” for patients 
[57]. A critical disadvantage of IRE is the inability to ablate large tumors (e.g. >3 cm in 
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diameter) under a safe electric field strength [58]. IRE relies on two or more needle 
electrodes to deliver the high-voltage pulses (Figure 1.6); however, the electric field 
intensity decreases with distance from an electrode [59]. If the electric field intensity 
drops below the effective electric field threshold (500–1000 V/cm depending on the cell 
type [46]), the cancer cells will be able to repair the membrane and remain viable, 
resulting in incomplete tumor ablation [60].  
 
Figure 1.6 Illustration of IRE-mediated tumor ablation. Needle electrodes are inserted 
into the tumor tissue to deliver the high-voltage pulses. Cells within the ablation volume 
will be exposed to electric field strengths above the effective threshold, leading to cell 
death. Reprinted from Radiology, v. 295, B. Geboers, H.J. Scheffer, P.M. Graybill, A.H. 
Ruarus, S. Nieuwenhuizen, R.S. Puijk, P.M. van den Tol, R. V. Davalos, B. Rubinsky, 
T.D. de Gruijl, D. Miklavčič, M.R. Meijerink, High-Voltage Electrical Pulses in 
Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, 
Electrofusion, and Electroimmunotherapy, p. 254-272, Copyright (2020), with 
permission from Radiological Society of North America. 
While it is possible to increase the ablation volume by increasing the electrode 
voltage, extremely high voltage can damage adjacent nerves and cardiac tissue [61,62] 
and heat can be generated in the proximity of the electrodes (due to Joule heating) [63]. 
Larger tumors can be treated with IRE by increasing the number of electrodes or 
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repositioning the electrodes; however, this increases the complexity and invasiveness of 
the procedure [46,58]. Repeated IRE treatments can be performed to try to fully ablate a 
tumor, but this is avoided when possible because patients must undergo general 
anesthesia and receive neuromuscular blocking agents to prevent uncontrolled severe 
muscle contractions from the electrical pulses. Additionally, cardiac monitoring and 
synchronized pulsing with heart rhythm is necessary to reduce the risk of inducing 
cardiac arrhythmias [47,54]. 
An attractive way to improve IRE is to lower the electric field threshold required to 
induce cell death. One way to do this is by sensitizing the cell membrane to make it more 
susceptible to IRE [60]. A number of molecules have been shown to sensitize cells to 
IRE, including cationic molecules (such as procaine, tetracaine, lidocaine, and 
polyarginine), sodium dodecyl sulfate (SDS, a small-molecule surfactant) and dimethyl 
sulfoxide (DMSO, a polar aprotic solvent) [46,58,64–66]. Membranolytic polymers may 
be able to similarly sensitize cell membranes to IRE to kill cells at moderate electric 
fields strengths and increase the ablation volume. 
1.6 Thesis Overview 
In this thesis, we aim to use biointerfacing polymers to overcome four challenges in 
vaccine delivery, gene therapy, and cancer therapy. Chapter 2 focuses on developing a 
simple biopolymer platform of mucoadhesive wafers that enables effective sublingual 
delivery and preservation of protein vaccines. In chapter 3, similar polymer wafers were 
used to enhance polyplex-mediated transfection in serum free and 10% serum conditions 
in vitro. Chapter 4 focuses on the use of a membranolytic polymer, poly (6-amino-1-
hexyl methacrylate) (PAHM) to disrupt cancer cell membranes to increase cellular uptake 
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of the chemotherapy drug doxorubicin (DOX) and synergistically kill cancer cells. In 
chapter 5, PAHM was combined with irreversible electroporation (IRE) to kill cancer 
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The sublingual mucosa is a highly attractive site of vaccination for multiple reasons. 
Accessibility of the oral cavity allows for self-administration of needle-free vaccine 
dosage forms. The oral mucosal environment is rather benign. Unlike enteric oral 
vaccines, sublingual vaccines are not subject to the hostile environment of the 
gastrointestinal tract and can avoid first-pass clearance by the liver [12,67]. The presence 
of a large population of antigen presenting cells (APCs) makes the sublingual mucosa an 
important site for antigen acquisition and presentation [12], since many viral and 
bacterial pathogens invade mucosal tissues [13]. While most intramuscular and 
subcutaneous vaccines confer systemic immunity, they often induce insufficient mucosal 
immunity [14]. Sublingual vaccines have been shown to confer mucosal immune 
responses and protective immunity against numerous pathogens, including influenza, 
SARS, RSV, HIV-1, and HPV [68]. Various sublingual vaccines have been shown to be 
safe and highly effective in several animal models [12]. However, despite the success in 
preclinical studies, sublingual vaccines are rarely used in humans. While sublingual 
immunotherapy (SLIT) has been used clinically to treat allergy and hypersensitivity, very 
few sublingual vaccines for infectious diseases have reached clinical stage [12,69].   
One factor limiting the success of sublingual vaccines is that their formulations are 
less than optimal. Sublingual vaccines are often delivered as liquid formulations [12]. 
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While these formulations enable convenient and exact dosing, they do not provide 
sufficient adhesion to and absorption through the sublingual epithelium. As a result, the 
liquid vaccines can be physically removed from the sublingual site (e.g., due to 
swallowing, talking, eating, drinking, or saliva wash-out) [70], resulting in poor 
immunogenicity. This is particularly problematic for protein vaccines. Despite the 
commercial success of sublingual delivery of small molecule drugs [20], macromolecules 
have been much harder to deliver by this route, presumably due to the sublingual 
epithelium acting as a low-permeability barrier [12,67]. Mucoadhesive delivery systems 
can be used to hold macromolecules in place at the delivery site, providing sufficient time 
for permeation into the sublingual mucosa [71]. Mucoadhesive dosage forms containing a 
variety of synthetic and biological polymers have been shown to improve the oral 
mucosal delivery of peptides [72] (such as insulin [73]), proteins [74–79] and DNA [19].  
Vaccine formulations generally contain highly sensitive and fragile biological 
molecules that are susceptible to denaturation and degradation due to exposure to 
elevated or fluctuating temperatures [80]. A cold chain is necessary to maintain vaccines 
under refrigerated condition throughout storage and distribution [81]. Considerable 
amount of work has been done on developing lyophilized vaccine formulations. These 
formulations generally contain various stabilizing excipients that can protect vaccines and 
prolong vaccine shelf-life [82,83]; however, the majority of FDA approved freeze-dried 
vaccines still require storage at 2 – 8 ºC and must be reconstituted in an appropriate 
buffer before use, which can lead to further loss of activity [81]. Recent reports on 
mucoadhesive sublingual delivery systems based on nanoparticles [25], patches [24], 
bilayer tablets [23] and films [19] have shown success in delivering peptides and proteins 
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such as insulin [25], lysozyme [24], ovalbumin [23], and β-galactosidase [19], but storage 
stability of the cargos was not adequately addressed and these vaccine formulations still 
required cold chain. 
While a large number of mucoadhesive polymers are available [84], the adoption of 
particular ingredients to create sublingual formulations seems to be based on trial and 
error and thus lacking rational design. The compositions of sublingual drug products are 
often unnecessarily complex. More importantly, very few have investigated stabilization 
of sublingual protein vaccines and none have demonstrated sufficient protection of the 
active protein components from environmental damage due to excess heat and 
lyophilization. On the other hand, although there is a large body of literature dedicated to 
protein stabilization and preservation without needing the cold chain, such systems have 
not been integrated with mucoadhesive materials and hence are not yet conducive to 
sublingual administration [82,85,86]. 
The objective of the present study is to develop a simple biopolymer platform of 
mucoadhesive wafers that enables effective sublingual delivery and preservation of 
lyophilized protein vaccines. The wafers were composed of a series of binary polymer 
blends of carboxymethylcellulose (CMC) and alginate (ALG) (Figure 2.1).  The 
influence of polymer composition on the microstructure, mechanical properties, 
disintegration time, release kinetics of model compounds, and mucoadhesive strength of 
the wafers was investigated. Ex vivo experiments were conducted to assess quantitatively 
the depth of permeation of a model protein (bovine serum albumin) into the sublingual 
submucosa and resistance to wash-out. β-galactosidase was used as a model for assessing 
the ability of the wafers to protect against inactivation during lyophilization and heat 
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challenge. Finally, wafers with the optimal composition were loaded with HIV gp140 
protein and used to vaccinate mice sublingually in combination with an adjuvant 
(αGalSer). The induction of antigen-specific mucosal and systemic immune responses 
was evaluated and compared with freshly prepared aqueous protein antigen. 
 
Figure 2.1 Rationale of design of mucoadhesive wafers consisting of binary polymer 
blends for sublingual delivery and stabilization of protein vaccines. 
2.2 Materials and Methods 
2.2.1 Chemicals and reagents 
ALG (sodium alginate from brown algae, viscosity of 1% aqueous solution at 20 ºC: 
100 – 200 cP), CMC (sodium salt, MW ~ 90 kDa, degree of substitution:  0.65 – 0.90, 
viscosity of 4% aqueous solution at 25 oC: 50 – 200 cP), bovine serum albumin (BSA), 
fluorescein (sodium salt), rhodamine B isothiocyanate (RBITC), 2-mercaptoethanol (2-
ME), 2-nitrophenyl β-D-galactopyranoside (ONPG), and β-galactosidase (β-Gal) from E. 
coli (grade VII, lyophilized powder, ≥ 500 units/mg protein) were from Sigma Aldrich 
(St. Louis, MO). Rhodamine B-labeled BSA (Rh-BSA) was prepared by reacting RBITC 
(50 μg in 50 μL DMSO) with BSA (1 mg in 1 mL PBS) for 2 h at room temperature 
followed by dialysis against phosphate buffered saline (PBS, 20 mM, pH 7) for 3 days. 
Dried Rh-BSA was obtained by lyophilization. Bovine submaxillary mucin (MW: 4 ~ 40 



































freshly prepared before use and contained KH2PO4 (0.19 mg/mL), Na2HPO4 (2.38 
mg/mL), NaCl (8 mg/mL), mucin (1 mg/mL), with pH adjusted to 6.8 [87]. The 
HIV/Clade C gp140 protein was obtained from AIDS Research and Reference Reagent 
Program (Germantown, MD). α-Galactosylceramide (αGalCer) was purchased from 
Diagnocine LLC (Hackensack, NJ).  
2.2.2 Preparation of blank and cargo-loaded polymer wafers 
Five aqueous stock solutions were prepared comprising the following CMC:ALG 
ratios (wt:wt): 0:1, 1:2, 1:1, 2:1, and 1:0 by dissolving appropriate amounts of the 
polymers as well as NaCl in deionized water at a final combined polymer concentration 
of 2.25% (w/v) and salt concentration of 150 mM. After brief heating at 70 ºC to 
facilitate complete dissolution of the polymers, 1 N NaOH was used to adjust the pH of 
the polymer solutions to 7. To prepare blank wafers, aliquots of 100 µL of the polymer 
solutions were dispensed in 96-well flat-bottom plates, frozen at -80 ºC overnight and 
lyophilized under 0.020 mBar for 72 h in a FreeZone ® Freeze Dry System (Labconco, 
Kansas City, MO) equipped with a Maxima™ C Plus Vacuum Pump (Model M8c, Fisher 
Scientific). After drying, the wafers were carefully removed from the wells and 
compressed to ~0.5 mm thick by applying a constant force of 30 pounds for 5 sec. 
Hundreds of wafers were prepared using this method. The wafers were weighed and the 
diameter and thickness were measured using a digital caliper. The same protocol was 
used to prepare polymer wafers containing various cargos, including fluorescein (0.3 
mg/wafer, for measuring in vitro release rate), Rh-BSA (0.3 mg/wafer, for measuring in 
vitro release rate and tissue penetration), β-Gal (0.3 Units/wafer, for evaluating 
stabilization against lyophilization and heat), HIV gp140 (5 µg/wafer, for testing 
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immunogenicity in mice). The cargos were added to and mixed with the polymer 
solutions before lyophilization. All the wafers were stored under ambient condition 
without desiccation. 
2.2.3 Scanning electron microscopy (SEM) 
To examine the surface morphology of the polymer wafers, SEM was performed 
using a Hitachi S-4700 Cold Field Emission Gun Scanning Electron Microscope (FEG-
SEM) operated at an accelerating voltage of 1.5 kV and an emission current of 10 µA. 
Prior to imaging, polymer wafers were adhered to SEM specimen stubs by double-sided 
carbon tape. 
2.2.4 Mechanical testing 
To perform tensile tests, each wafer was secured by a custom-made clamp, mounted 
on a Q Series Mechanical Test Machine (TestResources Inc., Shakopee, MN) and pulled 
at a constant speed of 1 mm/min until fracture. Data collection and analysis were 
performed using the XY Software package provided with the instrument. Tensile 
strength, Young’s modulus, and elongation at break were obtained from the recorded 
stress-displacement curves. 
2.2.5 Disintegration time and in vitro release kinetics 
Polymer wafers were submerged in 1 mL of fresh simulated saliva in 24-well plates at 
25 ºC. The disintegration time was determined as the time at which the wafers 
disintegrated and no residual material was visible to the naked eye. When wafers 
containing fluorescein or Rh-BSA underwent disintegration, 100 µL of the supernatant 
was sampled and replaced with fresh simulated saliva at particular time points. The 
amount of fluorescein or Rh-BSA in the supernatant was quantified by measuring 
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fluorescence emission intensity at 528 nm (fluorescein, excitation at 485 nm) and 590 nm 
(Rh-BSA, excitation at 530 nm) using a Synergy HT plate reader (BioTek Instruments, 
Winooski, VT). Release kinetic profiles were expressed as the cumulative percentage 
released over time. 
2.2.6 Ex vivo characterization of wafer adhesion to porcine sublingual mucosa 
Fresh sublingual mucosal tissue was harvested from Mongrel swine (average body 
weight: 30 – 40 kg), donated by the Iaizzo Visible Heart® Laboratory (Department of 
Physiology, University of Minnesota). The entire tongue of the pig with intact sublingual 
tissue on the ventral side was removed, cut into cubes (2.5 × 2.5 × 1.0 cm) and mounted 
onto a Q Series Mechanical Test Machine (TestResources Inc., Shakopee, MN) with a 
custom clamp. Prior to each measurement, 100 µL of freshly prepared simulated saliva 
was applied evenly to the mucosal tissue. Each polymer wafer was mounted onto a probe 
and slowly brought into contact with the mucosal tissue. A contact force of 50 mN was 
applied and held for 1 min to initiate adhesion between the wafer and the mucosal tissue. 
The probe was then pulled at a constant speed of 1 mm/min until the wafer was detached 
from the mucosal surface. Data collection and analysis were performed using the XY 
Software package provided with the instrument. The resulting stress-displacement plot 
was used to determine (1) maximum detachment stress (σmax), defined as the peak stress, 
and (2) work of adhesion per unit area (Wad), calculated as the area under the curve.  
2.2.7 Ex vivo permeation of Rh-BSA through porcine sublingual mucosa 
Fresh porcine tongue was cut into cubes (1.5 × 1.5 × 0.5 cm) and 50 µL of simulated 
saliva was applied evenly to the surface of the sublingual mucosal tissue. Wafers 
containing Rh-BSA were pressed to the wet sublingual tissue. For comparison, an 
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equivalent amount of free Rh-BSA in 10 µL of buffer was applied to a different piece of 
tissue. After two minutes, both mucosal surfaces were rinsed with 10 mL of deionized 
water for 20 sec to mimic saliva washout. Two hours later the tissues were examined for 
residual Rh-BSA on the mucosal surfaces, photographed, and embedded in Tissue-Tek® 
O.C.T (Sakura Finnetek USA, Torrance, CA), flash-frozen with liquid nitrogen and 
stored at -80 ºC overnight. Any residual wafer material was carefully removed from 
tissue surface before embedding in O.C.T. The frozen tissues were sectioned with a Leica 
CM1990 Cryostat (North Central Instruments, Plymouth, MN) to the thickness of 15 µm. 
Fluorescent and bright-field images of the tissue sections were acquired with an Olympus 
IX70 inverted fluorescence microscope equipped with an Olympus DP72 camera and X-
Cite 120 Wide-Field Fluorescence Microscope Excitation Light Source (Excelitas 
Technologies). Rh-BSA was visualized using an excitation wavelength of 535 ± 50 nm 
and emission wavelength of 610 ± 75 nm. An exposure time of 20 ms was selected for 
image capture to minimize tissue autofluorescence. The fluorescence intensity of the Rh-
BSA was quantified up to a permeation depth of 250 µm using a custom MATLAB script 
and averaging six different images for each sample. Total amount of Rh-BSA in the 
sublingual tissue was quantified by calculating the area under the fluorescence intensity-
permeation depth curves using GraphPad Prism version 8.2.1 (Graphpad software Inc., 
San Diego, California, USA). 
2.2.8 Assessment of β-Gal activity after lyophilization and heat challenge 
Polymer wafers containing β-Gal were reconstituted in phosphate buffer (93 mM Na 
phosphate, 1 mM MgCl2 and 112 mM 2-ME, pH 7.3). The substrate ONPG was added to 
a final concentration of 2.3 mM and incubated at 37 ºC for 6 min. The absorbance at 410 
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nm corrected for blank buffer background was recorded using a Synergy HT plate reader 
(BioTek Instruments, Winooski, VT). β-Gal activity was reported as Unit/mg enzyme, 
where one Unit of β-Gal will hydrolyze 1.0 µmol of ONPG per minute at pH 7.3 at 37 ºC 
[88]. Using this method β-Gal activity of the following samples was determined: (1) 
aqueous solutions of free β-Gal and polymers; (2) lyophilized free β-Gal and β-Gal-
containing polymer wafers; (3) lyophilized free β-Gal and β-Gal-containing polymer 
wafers after heating at 75 ºC for 30 min in a Dry Bath Incubator (Fisher Scientific). 
2.2.9 Animals 
Female CB6F1 (C57BL/6 X BALB/c) mice aged 6 – 10 weeks were purchased from 
the National Cancer Institute (Frederick, MD) and maintained in specific pathogen-free 
environment at the institutional animal facility at The University of Texas MD Anderson 
Cancer Center (Houston, TX). The animal facility is fully accredited by the Association 
for Assessment and Accreditation of Laboratory Animals Care International and all 
animal procedures were conducted in compliance with institutional approval (IACUC 
protocol number: 00000858-RN00). 
2.2.10 Sublingual immunization 
All wafers containing HIV gp140 were prepared at the University of Minnesota 
(Minneapolis, MN) and stored at room temperature without desiccation. They were 
packaged in zip-lock bags, shipped to the MD Anderson Cancer Center (Houston, Texas) 
with no refrigeration or desiccation, and stored on the bench under ambient condition for 
five days before in vivo testing. Mice in groups of five were first anesthetized by 
intraperitoneal injection of cocktail containing ketamine and xylazine hydrochloride (100 
mg/kg and 10 mg/kg, respectively). For administration of vaccine as liquid solution, 5 µg 
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(in 10 µL of PBS) of freshly thawed gp140 protein with 2 µg (in 2 µL of DMSO) of 
αGalCer, a natural killer T (NKT) cell agonist and adjuvant, was deposited under the 
tongue of each animal using a previously described procedure [15]. For administration of 
the vaccine formulated in polymer wafers, mice were placed in dorsal recumbency and a 
single wafer containing 5 µg of gp140 was folded using a pair of forceps and then 
positioned under the tongue of each anaesthetized mouse. αGalCer (2 µg) was co-
administered by depositing it sublingually on the wafer. To avoid swallowing, the 
animals were maintained with their heads in ante-flexion until they regained 
consciousness. All animals received two immunizations at 7-day intervals and both cell-
mediated and antibody-mediated adaptive immune responses in different tissues were 
determined on day 14 after the first immunization.  
2.2.11 Interferon-γ ELISpot assay 
IFN-γ ELISpot assay was used to determine the antigen-specific responses of T 
lymphocytes isolated from cervical lymph nodes (CLNs) and the lungs of the immunized 
animals at day 14 after the first immunization according to a previously described 
protocol [89,90]. The T cells were stimulated by incubating with either medium alone or 
gp140 protein (1 µM) or Concanavalin A (5 µg/mL) for 48 h before secondary antibody 
treatment and color development of IFN-γ spot forming cells (SFC) using the commercial 
reagent kit (BD Biosciences, San Jose, CA). Enumeration of spots representing individual 
cells producing IFN-γ was performed by Zellnet Consulting Inc., (Fort Lee, NJ) using 
KS-ELISPOT automatic system (Carl Zeiss Inc., Thornwood, NY). Responses were 
considered positive only when they were above 10 SFC/2 x105 input cells and at least 
twice the number obtained in cells cultured with medium alone.  
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2.2.12 Antigen-specific antibody responses 
Anti-gp140 antibody responses were evaluated in the blood, saliva and vaginal 
washes of immunized animals. Retro-orbital sinuses were used to collect blood samples. 
For collection of saliva, animals were first anaesthetized with ketamine and xylazine 
cocktail followed by induction of secretion of saliva by i.p. administration of pilocarpine 
(200 mg/kg). Saliva was collected using a micropipette. Vaginal washes were collected 
by repeated flushing with PBS. Serum (diluted 1:100) and mucosal secretions (diluted 
1:5) were assayed for gp140 specific antibody levels by ELISA using standard protocols 
[91]. Horseradish Peroxidase (HRP)-conjugated goat antibodies to mouse IgG or IgA 
(KPL Inc., Gaithersburg, MD) were used for detection. The gp140 specific antibody 
concentration in the sample was determined by subtracting the optical absorbance at 450 
nm of the pre-immunization samples from post-immunization sample for individual 
animals. For each group of five immunized mice, results were expressed as average 
absorbance ± SD. 
2.2.13 Statistical analysis 
ANOVA with Tukey’s multiple comparisons test was used to determine the 
significance between different wafer compositions. Holm-Sidak t-test for multiple 
comparisons with α = 0.05 was used to test Rh-BSA fluorescence intensity at each 
permeation depth. One-way ANOVA and Tukey HSD test for multiple comparisons were 
used to analyze the total amount of Rh-BSA present in the sublingual tissue. Paired two-
tailed Student’s t-test was used to determine the significance of difference between 
different immunization groups. All analyses were performed using GraphPad prism, 
version 8.2.1 (GraphPad software Inc., San Diego, California, USA). 
 31 
2.3 Results 
2.3.1 Appearance, microstructure, and mechanical properties of wafers 
The average diameter, thickness, and weight of 80 to 100 wafers of various polymer 
compositions were measured and results summarized in Table 2.1. All the CMC:ALG 
ratios formed wafers with highly consistent average weight (3.3-3.4 mg) and average 
dimensions (diameter: 6.51-6.53 mm; thickness: 0.54-0.56 mm) with the exception of the 
pure CMC wafers, which were smaller (average diameter: 5.37 mm) and thinner (average 
thickness: 0.50 mm). Visual inspection of the wafers clearly showed such differences 
(Figure 2.2A). The pure CMC wafers had significant shrinkage with irregular shape and 
large heterogeneous pores. In contrast, wafers containing various amounts of ALG were 
round with minimal shrinkage after lyophilization and were macroscopically 
homogeneous.  
In accordance with visual inspection, closer examination of the wafers by SEM 
revealed that different CMC:ALG ratio produced different microstructures. Pure CMC 
wafers had large pores and thick granular strands in the meshwork, whereas pure ALG 
wafers had much smaller pores and rather smooth polymer strands. Wafers with 
intermediate CMC:ALG ratios (such as 1:1) had intermediate pore sizes and morphology 
(Figure 2.2B).  
Table 2.1 Average size and weight of mucoadhesive wafers prepared via a simple and 










CMC 5.37 ± 0.75 0.50 ± 0.08 3.4 ± 0.2 
2:1 6.51 ± 0.18 0.54 ± 0.11 3.3 ± 0.2 
1:1 6.53 ± 0.18 0.56 ± 0.08 3.3 ± 0.2 
1:2 6.52 ± 0.16 0.54 ± 0.08 3.4 ± 0.2 
ALG 6.51 ± 0.16 0.56 ± 0.07 3.3 ± 0.2 
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Figure 2.2 Macroscopic appearance (A) and microstructure (B) of the mucoadhesive 
wafers revealed by SEM. 
Mechanical properties of the wafers were characterized by tensile test. The pure CMC 
wafers were rather stiff and brittle with the highest tensile strength and Young’s modulus 
and the lowest elongation at break among all compositions (Table 2.2). Wafers 
containing ALG were more elastic and much easier to handle. With increasing ALG 
content, the wafers showed a general trend of reduced strength and increased elasticity.  
Table 2.2 Mechanical properties of the mucoadhesive wafers. Data shown are mean ± 
SD (n=5). 
 
2.3.2 Disintegration time and release kinetics 
The polymer wafers were submerged in simulated saliva to determine how wafer 
composition would affect disintegration time. The pure CMC wafers disintegrated 
completely in 45 min, significantly faster than all other compositions, which disintegrated 
in 70-80 min (Figure 2.3A). Fluorescein (MW 376.28 g/mol) was released from the 










1 mm 1 mm 1 mm 
200 µm 200 µm 200 µm 










at break (%) 
CMC 314.8 ± 151.5 589.2 ± 152.2 65.5 ± 22.6 
2:1 66.6 ± 10.5 304.2 ± 69.5 91.7 ± 33.2 
1:1 78.6 ± 14.9 240.8 ± 91.5 111.2 ± 49.9 
1:2 70.6 ± 9.8 248.8 ± 99.2 113.4 ± 23.0 
ALG 80.7 ± 12.6 132.7 ± 97.6 151.6 ± 77.8 
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wafers with approximately first-order kinetics (Figure 2.3B). All compositions reached 
100% release after approximately 40 min, prior to the complete disintegration of the 
wafers. On the other hand, BSA (MW 66 kDa) was released more slowly than 
fluorescein, following approximately zero-order kinetics for 1 h before slightly leveling 
off (Figure 2.3C). BSA was released completely after approximately 75-90 min, 
coinciding with wafer disintegration.  
The results of fluorescein and BSA release kinetics from pure CMC, 1:1, and pure 
ALG wafers were fit using four models for drug release – first order, Higuchi, Hixson-
Crowell, and Korsmeyer-Peppas [92]. Fluorescein release data were best fit by the first 
order model (Table 2.3, Figure 2.4), whereas BSA release kinetics data were best fit by 
the Hixson-Crowell model (Table 2.4, Figure 2.5). 
 
Figure 2.3 Disintegration time of mucoadhesive wafers and release kinetics of model 
compounds.  (A) Average time of wafer disintegration in simulated saliva. (B) Release 
kinetics of fluorescein and (C) BSA in simulated saliva at 25 ºC. Data are shown as mean 
± SD. (A) ANOVA and Tukey HSD test, n=14-18, ns: no significant difference among 
wafers containing ALG. (B) n=16, data fit with a first-order kinetic model. (C) n=8, data 







































Table 2.3 Release kinetics of fluorescein fit with four mathematical models (First-Order, 
Higuchi, Hixson-Crowell, Korsmeyer-Peppas). Highlighted column indicates the model 
that best fits the data. 
 
 
Figure 2.4 Release kinetics of fluorescein fit with four mathematical models (First-
Order, Higuchi, Hixson-Crowell, Korsmeyer-Peppas). Data are shown as mean±SD 
(n=16). Wafer composition: (A) pure CMC, (B) CMC:ALG = 1:1, (C) pure ALG. 
Table 2.4 Release kinetics of BSA fit with four mathematical models (First-Order, 
Higuchi, Hixson-Crowell, Korsmeyer-Peppas). Highlighted column indicates the model 
that best fits the data. 
 
 
Figure 2.5 Release kinetics of BSA fit with four mathematical models (First-Order, 
Higuchi, Hixson-Crowell, Korsmeyer-Peppas). Data are shown as mean±SD (n=8). 
Wafer composition: (A) pure CMC, (B) CMC:ALG = 1:1, (C) pure ALG. 
First-Order
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2.3.3 Strength and energetics of mucoadhesion 
Fresh porcine sublingual mucosal tissue was used to evaluate the mucoadhesive 
strength of polymer wafers with various compositions. A typical stress-displacement 
curve (Figure 2.6A) shows an initial increase in stress due to elastic stretching of the 
mucosal tissue to which the wafer remained attached. As the wafer started to be peeled 
off the mucosal surface, stress eventually decreased to zero when the wafer detached 
completely from the mucosal surface. Wafers of higher CMC content showed higher σmax 
(Figure 2.6B), whereas mixed CMC/ALG content tend to have higher Wad (Figure 2.6C). 
The brittle pure CMC wafers fractured prior to separation from the mucosal tissue; 
however, the other wafer compositions elongated elastically before peeling away from 
the tissue and did not fracture. 
 
Figure 2.6 Mucoadhesive properties of the wafers. The wafers were attached to the 
surface of porcine sublingual mucosa wet by simulated saliva and tensile tests were 
performed at room temperature. (A) Representative stress-displacement of wafer 
detaching from mucosal surface. (B) Maximum detachment stress (σmax). (C) Work of 
adhesion per unit area (Wad), calculated as area under the stress-displacement curve. Data 
are shown as mean ± SD (n=15). ANOVA with Tukey HSD test, ns: not significant. 
2.3.4 Permeation into sublingual mucosa 
Porcine sublingual mucosa tissue was used to assess the permeation of fluorescently 























































aqueous buffered solution (0.3 mg per dose). First, the free protein solution created a 
localized, somewhat diffusive stain on the mucosal surface, but later it was completely 
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Figure 2.7 Mucoadhesive wafers prevent saliva wash-out and enhance permeation of 
model protein into porcine sublingual mucosa. (A) Surface of sublingual mucosa after 
washing with 10 mL of deionized water for 20 sec. (B) Representative fluorescence 
microscopy images of Rh-BSA permeation into sublingual mucosa. (C, D) Fluorescence 
intensity of Rh-BSA at various depths beneath the tissue surface. (E) Total amount of Rh-
BSA present in the sublingual mucosa. Data are shown as mean ± SD (n=5-6 tissue 
slices). (C-D) Holm-Sidak t-test, α=0.05, (E) One-way ANOVA and Tukey HSD test, ns: 
not significant. 
In contrast, the wafer adhered strongly to the mucosal surface and maintained high 
local protein concentration despite water wash.  Next, the Rh-BSA was allowed to 
permeate into the sublingual mucosa for 2 h, at which time the tissue was sectioned and 
imaged. Representative fluorescent micrographs revealed that the 1:1 wafers yielded 
much greater depth of Rh-BSA permeation into the sublingual mucosa in comparison 
with free protein solution (Figure 2.7B). As expected, wafers with higher ALG 
concentration (1:2 and pure ALG) could not remain adhered to the mucosal tissue during 
washing. Quantification of the fluorescence intensity (Figure 2.7C-E) reveals that wafer-
delivered Rh-BSA permeated to depths greater than 200 µm, beyond the 100-200 µm 
thick epithelium, even under the condition mimicking wash-out [93].  
2.3.5 Preservation of protein activity 
To assess the protein stabilization capabilities, β-galactosidase (β-gal) was loaded into 
the polymer wafers and the enzyme activity was quantified and compared with that of the 
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solid (Figure 2.8A). One unit will hydrolyze 1.0 µmol of the substrate ONPG per minute 
at pH 7.3 and 37 ºC. First, fresh β-gal was dissolved in various polymer aqueous 
solutions and the enzyme activity was measured. There was minimal but statistically 
significant effect on β-gal activity by CMC and ALG in aqueous solutions (Figure 2.8A). 
Next, β-gal activity was determined after lyophilization of the enzyme in the presence or 
absence of various polymer blends. As expected, lyophilization of free β-gal resulted in a 
22.5% reduction in activity (Figure 2.8B). Surprisingly, β-gal in pure CMC wafers had a 
~80% reduction in activity. In contrast, β-gal in wafers containing various amounts of 
ALG (especially 1:1 and 1:2 CMC:ALG ratios) appeared to remain fully active (Figure 
2.8B). Finally, the various wafer formulations and free protein solids were treated at 75 
ºC for 30 min. As expected, free unprotected β-gal lost 60% of the initial activity due to 
heat challenge (Figure 2.8C). Again, the pure CMC wafers caused β-gal to lose nearly 
95% of its initial activity. In contrast, the 1:1 and pure ALG wafers preserved nearly 70% 
of the initial β-gal activity. 
 
Figure 2.8 Mucoadhesive wafers protect β-Galactosidase (β-gal) from deactivation due 
to lyophilization and heat challenge. Enzyme activity was measured (A) prior to 
lyophilization, (B) after lyophilization (reconstitution in 100 mM PBS, pH 7.3), and (C) 
after lyophilization and heat challenge (75 ºC for 30 min). Data are shown as mean ± SD 
(n=6-18). ANOVA with Tukey HSD test, ns: not significant. Grey shaded area indicates 
the range of activity of free enzyme in buffer without lyophilization or heat challenge. 
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2.3.6 Vaccine efficacy in vivo 
Mice were immunized by the sublingual route with HIV gp140 protein, which was 
formulated as freshly thawed aqueous solution or in polymer wafers of 1:1 CMC:ALG 
ratio. In the lungs, polymer wafer delivery of gp140 appeared to generate greater T cell 
response (136 SFU/2 × 105 cells) to the fresh gp140 liquid solution (57 SFU/2 × 105 
cells), although the difference was not statistically significant (Figure 2.9A).  
 
Figure 2.9 Mucoadhesive wafers achieve equal or better immune responses to an HIV 
gp140 vaccine after sublingual delivery in mice. (A) IFN-γ (by ELISPOT). (B) IgG and 
(C) IgA (by ELISA, serum samples diluted 1:100; mucosal secretions diluted 1:5). Mice 
were vaccinated sublingually with 5 µg of gp140 protein either as fresh solution in buffer 
or as wafer after storage at room temperature for one week. All mice were also given 2 
µg of αGalCer sublingually as adjuvant. Two immunizations were given on days 0 and 7. 
Mice were sacrificed on day 14. Data shown are mean ± SD (n=5). Two-tailed t-test, ns: 
not significant. 
In the CLNs, polymer wafers generated greater T cell response (29 SFU/2 × 105 cells) 
than the fresh liquid solution (20 SFU/2 × 105 cells). Antibody responses were evaluated 
by measuring anti-gp140 IgG and IgA in the blood, saliva, and vaginal washes of 
immunized animals. Polymer wafers and fresh liquid solution were equally potent in 
inducing systemic antibody responses, as IgG antibody levels in serum, saliva, and 
vaginal washes were comparable for both formulations (Figure 2.9B). Similar results 
were seen in the mucosal antibody response, as IgA antibody levels in serum, saliva, and 































































vaginal washes were comparable between groups immunized by polymer wafers and 
fresh liquid solution (Figure 2.9C).  
2.4 Discussion 
The sublingual mucosa is an attractive site of vaccination for the development of 
robust mucosal immunity against many pathogens [94–96]. Mucoadhesive formulations 
have been used widely to deliver small molecules across the oral mucosa, including in 
some commercial products [97,98]. In contrast, the oral mucosal delivery of 
macromolecules (including protein and nucleic acid-based antigens and adjuvants) has 
been much less successful. A wide variety of mucoadhesive polymers, such as chitosan, 
cellulose derivatives, poly(acrylic acid), guar or other gums, polyvinyl alcohol, and 
polyvinylpyrrolidone, are available for use in sublingual drug formulations [84]. 
However, the compositions of sublingual drug products are often complex. The selection 
of appropriate mucoadhesive polymers is largely based on trial and error and thus lacking 
of rational design. Furthermore, most mucoadhesive formulations of proteins do not 
address the important issue of preserving protein stability against excess heat and 
lyophilization.  
The motivation of this study is to address the unmet need for a simple sublingual 
vaccine delivery system capable of both enhancing vaccine delivery efficiency through 
mucoadhesion and protecting bioactive protein antigens from environmental damage 
without the cold chain. We focused on binary blends of CMC and ALG, two biopolymers 
with excellent record of safety in human use. Our rationale is that each polymer would 
have a primary function, providing either strong mucoadhesion or protein stabilization, 
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and that adjusting the ratio of the two would allow optimization of the overall 
performance of the delivery system (Figure 2.1).  
CMC is an anionic derivative of cellulose and highly soluble in water [99]. Similar to 
cellulose, CMC is primarily a crystalline polymer (crystallinity index ~80%) [100]. At 
low degrees of substitution (DS < 1.0), molecular association between the unsubstituted 
regions of the CMC chains form crystalline regions with a similar structure to cellulose 
[101]. CMC is a widely used excipient for oral drug formulation and has been shown to 
exhibit good mucoadhesive properties [102,103] resulting from extensive physical 
entanglement and hydrogen bonding between the CMC chains and mucin [104], a main 
component of the mucosal surfaces [105]. ALG is another natural anionic polysaccharide 
and has been used in a range of drug delivery applications. A linear copolymer, ALG 
consists of homopolymeric regions of 1,4′-linked β-D-mannuronic and α-L-guluronic 
acid blocks [106]. Unlike CMC, ALG is a semi-crystalline with a typical crystallinity 
index of 30% [107]. While ALG was reported to be somewhat mucoadhesive [84], its 
primary purpose here is to stabilize proteins through a number of mechanisms [82] and to 
form mechanically robust films [108].  
We developed a simple yet robust process of lyophilizing binary blends of CMC and 
ALG with a range of mass ratios to form porous wafers. Hundreds of wafers were 
prepared using this method to achieve high consistency with regard to wafer diameter, 
thickness and weight (Table 2.1). The only outliers were wafers made of pure CMC; they 
were smaller in diameter and appeared shrunken with large pores (Figure 2.2A). 
Microstructural analysis shows that pure CMC wafers had large pores with thick strands, 
whereas increasing ALG content made the pores smaller and strands smoother (Figure 
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2.2B). Formation of these microstructures is likely due to the different degrees of 
crystallinity between CMC and ALG. During freezing the highly crystalline CMC may 
have phase-separated from water, allowing large ice crystals to form [109]. The 
subsequent sublimation of the ice crystals would leave behind the large pores seen in the 
CMC wafers. In contrast, the amorphous ALG chains are more flexible and mobile, 
allowing them to entangle and form more extensive networks [110]. These networks may 
have prevented ice crystal growth, resulting in much smaller pores after lyophilization. 
The network-forming capacity and low crystallinity of ALG can also explain the 
observation that wafers with increasing ALG content were less strong but more elastic 
(Table 2.2) and that the pure CMC wafers were brittle and difficult to handle. 
Interestingly, the pure CMC wafers did not display the optimal mucoadhesive 
behavior, although it was chosen primarily for its mucoadhesive properties. While pure 
CMC wafers adhered most strongly, as shown by the highest σmax (Figure 2.6B), wafers 
with moderate ALG content (2:1 and 1:1) had the largest Wad (Figure 2.6C). The 
elasticity of the ALG-containing wafers enabled them to deform and peel away from the 
porcine mucosal tissue under tension (Figure 2.6A), contributing to the greater Wad, 
whereas the pure CMC wafers fractured prior to detachment. While 1:1 wafers remained 
adhered to the sublingual mucosal tissue during extensive washing, wafers with higher 
ALG content (1:2 and pure ALG) could not withstand the wash and detached from the 
tissue. This is likely due to the lower work of adhesion (Wad) of wafers with high ALG 
content (Figure 2.6C). These results clearly demonstrate that a proper balance of 
mucoadhesive strength and mechanical cohesiveness, exemplified in wafers of 
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intermediate CMC:ALG ratios (such as the 1:1), is necessary for achieving the optimal 
performance in sublingual administration and the resistance to saliva wash-out. 
Microstructural differences between CMC and ALG also affected the disintegration 
time of the wafers and the release kinetics of model compounds. The larger pores found 
in the CMC wafers may allow water to more quickly hydrate the polymer matrix, 
resulting in significantly faster disintegration of the wafers (Figure 2.3A). The release 
mechanisms of fluorescein and BSA are notably different. A first-order model best fit the 
fluorescein release kinetics (Table 2.3, Figure 2.4). This suggests that fluorescein release 
was primarily diffusion dependent. The observation that fluorescein was 100% released 
from all wafer compositions prior to complete disintegration of the wafers can be 
explained by the fact that fluorescein, a highly soluble small molecule, may diffuse 
quickly upon hydration in the simulated saliva. On the other hand, the release kinetics of 
BSA was best fit by the Hixson-Crowell cube root law (Table 2.4, Figure 2.5), suggesting 
that BSA release is more dependent on wafer disintegration and less on diffusion. This 
mechanism is also consistent with the observation that complete release of BSA was 
achieved only after the wafers had completely disintegrated. The reliance on wafer 
disintegration may also explain the greater differences in BSA release kinetics among 
various wafer compositions (Figure 2.3C) as compared to the less significant differences 
in fluorescein release kinetics (Figure 2.3B).  
The effective pore radius of the sublingual mucosal membrane has been estimated at 
30–53 Å [111]. Therefore, many proteins, such as BSA (Rg ~ 30 Å) [112] and HIV gp140 
(Rg ~ 42 Å) [113], can likely diffuse through the sublingual epithelium, albeit very 
slowly. Mucoadhesive formulations may improve sublingual delivery of proteins by 
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providing sufficient time for these large molecules to diffuse into the tissue [67,71] as we 
have demonstrated here (Figure 2.7). Even during extensive washing with a large volume 
of water, the wafers of 1:1 CMC:ALG ratio remained adhered to the mucosal tissue. Over 
the course of 2 h, BSA delivered via the wafers was found inside the tissue at depths 
greater than 200 µm, within and beyond the 100 – 200 µm thick epithelium, whereas 
BSA delivered as aqueous solution never reached beyond 100 µm (Figure 2.7C,D). 
Therefore, with the help of these wafers, it is expected that protein antigens of similar 
size would reach the APCs within the epithelium and the underlying submucosa, eliciting 
antigen-specific immune responses. 
To preserve vaccine potency during lyophilization and storage, numerous excipients 
have been investigated to stabilize proteins against heating, freezing and dehydration 
[114]. Here we have shown that although both CMC and ALG are highly hydrophilic and 
have similar chemical features capable of hydrogen bonding, ALG was much effective 
than CMC in maintaining β-gal activity after lyophilization and heat challenge (Figure 
2.8). Due to its high crystallinity, the CMC chains may be too sterically hindered to form 
sufficient hydrogen bonds with β-gal to maintain its native structure. In contrast, the 
amorphous ALG chains are more flexible and thus able to hydrogen bond with β-gal. 
Surprisingly, pure CMC wafers compromised β-gal activity beyond that of the 
unprotected free protein after lyophilization. Perhaps phase separation of the highly 
crystalline CMC domains during freezing may have caused β-gal to aggregate and lose 
activity.  
We selected the 1:1 CMC:ALG blend as the optimal wafer composition after a 
balanced consideration of wafer mechanical robustness, mucoadhesive properties, and the 
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effectiveness of protein stabilization. This wafer composition was used to formulate a 
protein antigen, HIV gp140 protein. Wafer preparation was conducted at the University 
of Minnesota (Minneapolis, Minnesota) and shipped by air to MD Anderson Cancer 
Center (Houston, Texas) without refrigeration or desiccation. The wafers were then 
stored under ambient conditions for 5 days prior to sublingual immunization of mice. 
When compared to a freshly thawed liquid gp140 solution, the wafer vaccine generated 
comparable cell-mediated and antibody-mediated responses (Figure 2.9). T-cell response 
in the lungs were equally generated by the wafers and fresh liquid solutions. In the CLNs, 
greater T-cell response was seen when gp140 was given via the mucoadhesive wafers. 
Equally potent antibody responses were seen in mice immunized by wafers or liquid 
solution, as anti-gp140 IgG and IgA levels in the blood, saliva, and vaginal washes of 
both groups were comparable. Taken together, these results demonstrate that the 
mucoadhesive wafers of 1:1 binary composition is an effective sublingual protein vaccine 
formulation, capable of eliminating the need for cold-chain during storage and 
transportation and eliciting antigen-specific immune responses equal to or better than 
liquid protein formulation. Future studies on these binary polymer wafers will involve 
sublingual testing in larger animal models without anesthesia, in which case the 
anticipated advantage of mucoadhesive wafers over liquid formulation is expected to be 
more prominent considering saliva wash-out and swallowing. Another future opportunity 
is the co-encapsulation and controlled release of both antigen and immunostimulatory 
adjuvant using the same wafer formulation. 
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2.5 Conclusions 
We have prepared and characterized porous wafers consisting of blends of two 
biocompatible polymers – CMC and ALG – through a simple and robust process. Wafers 
with high CMC content was highly mucoadhesive to sublingual mucosal tissue and could 
withstand extensive washing, leading to improved protein permeation into the tissue. 
Wafers with high ALG content were not only mechanically robust, but also able to 
preserve the activity of a model enzyme from potential damage due to lyophilization and 
excessive heat. HIV gp140 protein encapsulated in wafers of the optimal composition 
(CMC:ALG ratio = 1:1) could be stored and transported without cold chain and 
maintained antigen-specific immunogenicity after sublingual vaccination in mice. These 
findings established that the CMC:ALG binary blend polymer wafers have the potential 
to improve the delivery and storage stability of sublingual protein-based vaccines.  
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Chapter 3 Enhancing Polyplex-Mediated Gene Delivery in vitro by Polyvinyl 
Alcohol Wafers 
3.1 Introduction 
Nucleic acid-based therapeutics, or “gene therapy”, has the potential to treat 
numerous diseases, such as cancer, neurodegenerative diseases, infectious diseases, and 
genetic disorders [115]. Gene therapy involves delivering DNA or RNA to replace or 
knockdown genes in target cells [37]. For gene therapy to be effective, an efficient carrier 
for the delivery of the genetic material is required [35]. While viral vectors have been 
shown to be efficient gene delivery systems, they have a limited genetic payload and can 
be difficult to produce in commercially relevant quantities [116,117]. Additionally, their 
potential safety concerns, such as immunogenicity and oncogenicity, have limited their 
clinical applications [36]. Consequently, the development of nonviral gene delivery 
systems has gained significant interest [118]. 
While intramuscular injection of naked plasmid DNA (pDNA) can produce detectable 
amounts of proteins in skeletal muscle, naked pDNA-based gene therapy has a low 
delivery efficiency, and as a result, low therapeutic effect [119]. Over 98% of injected 
pDNA has been shown to be degraded by extracellular nucleases or removed from the 
muscle within minutes after administration [120]. Numerous synthetic carriers have been 
developed to improve the delivery efficiency of pDNA. Many are based on cationic 
polymers which condense the negatively charged pDNA via electrostatic interactions to 
form “polyplexes.” Polyplexes can protect pDNA from nuclease degradation and 
facilitate cellular uptake [35]. Among the cationic polymers, polyethyleneimine (PEI) is 
the most commonly used polymer to form polyplexes for gene delivery [33]. The 
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repeating amine structure gives PEI a large positive charge density, which allows it to 
produce compact and tightly bound complexes with pDNA and electrostatically interact 
with negative charged cell membranes [36]. In addition, the substantial secondary and 
tertiary amines in branched PEI are thought to facilitate escape from endocytic vesicle via 
the “proton-sponge” mechanism [121], a crucial step in efficient gene delivery. 
Despite the high transfection efficiency of PEI polyplex-mediated gene delivery 
demonstrated in serum-free in vitro conditions, PEI polyplexes perform poorly in the 
presence of serum, limiting their efficacy in vivo [36]. Serum contains various negatively 
charged proteins that adsorb onto polyplexes, which can lead to polyplex aggregation, 
polyplex unpackaging, and reduced uptake by endocytosis [35]. In addition, various 
components of the extracellular matrix have been shown to bind to or unpackage 
polyplexes [34]. Many approaches have been investigated to reduce serum protein 
adsorption onto polyplexes to improve transfection efficiency in the presence of serum, 
including PEGylation [34], succinylation of PEI to form zwitterion-like polyplexes [36], 
covalently attaching polyvinyl alcohol (PVA) to PEI [35], and embedding polyplexes into 
PVA hydrogels [37,38].  
The objective of the present study is use polymer wafers to enhance polyplex-
mediated transfection in serum free and 10% serum conditions in vitro. The wafers were 
composed of different water-soluble polymers – carboxymethylcellulose (CMC), alginate 
(ALG), polyvinyl alcohol (PVA), hydroxypropyl cellulose (HPC), polyethylene oxide 
(PEO), or polyvinylpyrrolidone (PVP). Polyplexes encoding for green fluorescent protein 
(GFP) were loaded into the polymer wafers by a simple and robust process. Transfection 
efficiency of mouse fibroblast cells (NIH/3T3) was visualized with fluorescence 
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microscopy and quantified by flow cytometry. Lastly, the importance of the physical 
form of PVA in facilitating high transfection efficiency, especially in 10% serum 
containing medium, was investigated. 
3.2 Materials and Methods 
3.2.1 Chemicals and reagents 
Polyvinyl alcohol (PVA, 88 mol% hydrolyzed, MW 25 kDa, Polydispersity ~1.9) was 
purchased from Polysciences (Warrington, PA). Hydroxypropyl cellulose (HPC, average 
Mw ~100 kDa), polyvinylpyrrolidone (PVP, average Mw 360 kDa), polyethylene oxide 
(PEO, average Mv 600 kDa), polyethyleinime (PEI, branched, average Mw ~25 kDa by 
LS, average Mn ~10 kDa by GPC), paraformaldehyde, and bovine serum albumin (BSA) 
were purchased from Millipore Sigma (Burlington, MA). Green fluorescent protein 
(GFP) plasmid DNA (pEGFP-N1, 1 mg/mL in water) and Luciferase (Luc) luciferase 
(pCMV-Luc, 1 mg/mL in water) were purchased from Elim Biopharm (Hayward, CA). 
Dulbecco’s modified eagle medium (DMEM), fetal bovine serum (FBS), Penicillin-
Streptomycin (10,000 U/mL; 10,000 µg/mL), L-glutamine (200 mM), phosphate buffered 
saline (PBS, pH 7.4), sodium pyruvate (100 mM), trypsin-EDTA (0.25%), trypan blue 
(0.4% solution, 0.85% NaCl), HEPES buffer (1 M), Live Cell Imaging Solution (LCIS), 
NucBlue Live ReadyProbes Reagent (Hoechst 33342), sodium azide, MTT (3-(4,5-
dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide) (MTT), and dimethyl sulfoxide 
(DMSO) were purchased from Thermo Fisher Scientific (Waltham, MA). 
3.2.2 Preparation of PEI/DNA polyplexes 
PEI/DNA polyplexes with N/P ratio 8 or 11 were prepared by adding 1 mL of PEI 
solution (N/P: 8, 82.5 µg/mL in 20 mM HEPES buffer; N/P: 11, 112 µg/mL in 20 mM 
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HEPES buffer) to 1 mL of DNA plasmid solution (80 µg/mL in 20 mM HEPES buffer). 
Solutions were vortexed for 10 sec and incubated at room temperature (protected from 
light) for 30 minutes. 
3.2.3 Preparation of blank and polyplex-loaded polymer wafers 
Aqueous stock solutions of CMC, ALG, CMC:ALG (1:1 wt:wt), PVA, HPC, PEO, or 
PVP were prepared by dissolving the appropriate amounts of the polymers in deionized 
water at a concentration of 2.5% (w/v). The solutions were briefly heated at 60ºC to 
facilitate complete dissolution of the polymers. To prepare blank wafers, aliquots of 100 
µL of the polymer solutions were dispensed in 96-well flat-bottom plates, frozen at -80ºC 
overnight and lyophilized under 0.020 mBar for 72 h in a FreeZone® Freeze Dry System 
(Labconco, Kansas City, MO) equipped with a Maxima™ C Plus Vacuum Pump (Model 
M8c, Fisher Scientific). After drying, the wafers were carefully removed from the wells 
and compressed to ~0.5 mm thick by applying a constant force of 30 pounds for 5 sec. 
The same protocol was used to prepare polymer wafers containing naked plasmid DNA 
(2 µg DNA) or PEI/DNA polyplexes (2 µg DNA, N/P: 8 or 11). The cargo solutions (50 
µL) were added to and mixed with the polymer solutions (100 µL) before lyophilization. 
All the wafers were stored under ambient conditions (protected from light) without 
desiccation. 
3.2.4 Cell culture 
Mouse fibroblast cell line NIH/3T3 was obtained from ATCC. NIH/3T3 cells were 
cultured in a medium consisting of DMEM with 4.5 g/L glucose, 4 mM L-glutamine, 110 
mg/L sodium pyruvate, 3.7 g/L sodium bicarbonate, 10% heat inactivated fetal bovine 
serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin. NIH/3T3 cells were 
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cultured in tissue culture flasks and incubated in a humidified environment at 37ºC with 
5% CO2. When cells reached ~80% confluency the culture medium was removed, cells 
were rinsed with PBS, and 0.25% trypsin-EDTA was added for 5 min to detach cells 
from the flasks. Harvested cells were centrifuged at 200 x g for 5 min and supernatant 
was discarded. Cell pellets were resuspended in cell culture medium and a 100 µL aliquot 
was stained 1:1 with trypan blue 0.4% solution and counted using a hemocytometer and 
inverted microscope. Cell suspensions were split 1:3 to 1:6 to continue culture or diluted 
to the appropriate seeding density for subsequent experiments. 
3.2.5 Transfection efficiency of NIH/3T3 cells 
Harvested NIH/3T3 cells were diluted to density of 50,000 cells/mL and plated in 12-
well plates (50,000 cells/well). Cells were incubated in a humidified environment at 37ºC 
with 5% CO2 overnight (~18-24 h). Prior to transfection, the culture medium was 
removed, the cells were washed twice with 1 mL PBS, and the culture medium was 
replaced with 1 mL serum free or 10% serum containing media. Cells were transfected 
PEI/DNA polyplexes (2 µg DNA, N/P: 8 or 11). Polyplexes were given to cells in 
different delivery vehicles – polyplexes alone (in 50 µL HEPES buffer, 20 mM), 
polyplex-loaded polymer wafers, polyplex mixed in polymer solutions (without 
lyophilization), or polyplex-loaded polymer wafers reconstituted in 1 mL serum free or 
10% serum containing media (prior to transfection). After 4 h incubation in a humidified 
environment at 37ºC with 5% CO2, transfection media was removed, the cells were 
washed twice with 1 mL PBS, and the transfection media was replaced with 1 mL fresh 
cell culture medium. Cells were incubated in a humidified environment at 37ºC with 5% 
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CO2 overnight for 24 h or 48 h, after which transfection efficiency was analyzed with 
fluorescence microscopy and flow cytometry. 
Prior to fluorescence imaging, culture medium was removed, cells were washed twice 
with 1 mL PBS, and the medium was replaced with 1 mL LCIS. Cell nuclei were stained 
with Hoechst 33342 by adding 2 drops of NucBlue Live ReadyProbes Reagent to each 
dish followed by incubation in a humidified environment at 37ºC with 5% CO2 for 20 
min. Phase contrast and fluorescent images of NIH/3T3 cells were acquired with an 
Olympus IX70 inverted microscope equipped with an Olympus plan fluorite 20XPH/0.45 
NA objective, an Olympus DP72 camera, and an X-Cite 120 Wide-Field Fluorescence 
Microscope Excitation Light Source (Excelitas Technologies, Waltham, MA). Hoechst 
33342-stained cell nuclei were visualized using an excitation wavelength of 350 ± 50 nm 
and emission wavelength of 460 ± 50 nm. GFP+ cells were visualized using an excitation 
wavelength of 480 ± 40 nm and emission wavelength of 535 ± 50 nm. Exposure times 
were chosen to minimize autofluorescence. Images were analyzed in ImageJ. 
Prior to quantifying transfection efficiency with flow cytometry, culture medium was 
removed and cells were detached from the wells with 200 µL 0.25% trypsin-EDTA. After 
5 min incubation, cells were washed with 1 mL FACS buffer (PBS pH 7.4, 1% BSA, 
0.05% sodium azide), collected in FACS tubes (12 x 75 plastic culture tubes; Thermo 
Fisher Scientific, Waltham, MA), and fixed with 2% paraformaldehyde for 20 min. After 
fixation, cells were centrifuged to pellet, washed with 1 mL FACS buffer, and 
resuspended in 0.5 mL FACS buffer. Cells were stored at 4ºC (protected from light) until 
use. Analysis of 30,000 cells was done using a BD Accuri C6 flow cytometer (BD 
Biosciences, San Jose, CA). Data was analyzed FlowJo, version 10.7.1 (Ashland, OR). 
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Transfection efficiency was determined by quantifying the percentage of GFP+ cells and 
the mean fluorescence intensity (MFI) of GFP+ cells. The GFP+ gate was drawn based 
on cells transfected with Luc polyplexes delivered by equivalent vehicle (i.e., Luc 
polyplex alone, Luc polyplex-loaded wafer, Luc polyplex mixed in polymer solution, 
reconstituted Luc polyplex-loaded wafer). The false positive frequency was restricted to 
0.2%. 
3.2.6 Biocompatibility of PEI/DNA polyplexes 
Harvested NIH/3T3 cells were diluted to density of 50,000 cells/mL and plated in 12-
well plates (50,000 cells/well). Cells were incubated in a humidified environment at 37ºC 
with 5% CO2 overnight (~18-24 h). Cells were transfected with PEI/DNA polyplexes as 
described above in serum free or 10% serum containing media for 4 h. Transfection 
media was removed, cells were washed twice with 1 mL PBS, and the transfection media 
was replaced with 1 mL fresh cell culture medium (without phenol red). After 24 h 
incubation in a humidified environment at 37ºC with 5% CO2, cell viability was 
evaluated using an MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) assay [122]. To each well, 100 µL MTT solution (5 mg/mL in PBS) was added. 
After 4 h incubation in a humidified environment at 37ºC with 5% CO2, 850 µL medium 
was removed from each well. Formazan crystals were dissolved in 500 µL DMSO and 
absorbance was measured at 540 nm and corrected for blank media background using a 
BioTek Cytation 3 Cell Imaging Multi-Mode Reader BioTek Instruments, Winooski, 
VT). Cell viability was determined by normalizing by the absorbance of untreated cells. 
 54 
3.2.7 Measurement of PEI/DNA polyplex diameter by dynamic light scattering (DLS) 
PEI/DNA polyplexes (4 µg DNA, N/P: 8 or 11) were added to 2 mL serum free or 
10% serum containing media in 12 well plates and incubated in a humidified 
environment at 37ºC with 5% CO2 for 4 h. At particular time points, 1.5 mL was sampled 
and transferred to semi-micro cuvettes (Thermo Fisher Scientific, Waltham, MA). The 
effective diameter and half width of the polyplexes were measured using a Brookhaven 
90Plus Particle Size Analyzer (15 mW laser, 658 nm incident beam, 90% scattering 
angle; Brookhaven Instruments, Holtsville, NY). 
3.2.8 Statistical analysis 
ANOVA and Tukey HSD test for multiple comparisons were used to determine the 
significance of difference in GFP+, MFI, and cell viability between different treatment 
groups. All analyses were performed using GraphPad prism, version 9.0.0 (GraphPad 
software Inc., San Diego, California, USA). 
3.3 Results 
3.3.1 Transfection by polyplexes loaded into anionic polymer wafers 
Polyplexes (N/P: 11) were loaded into polymer wafers composed of the anionic 
polymers CMC, ALG, or 1:1 CMC:ALG ratio. The transfection of NIH/3T3 cells in 
serum free medium by polyplex-loaded anionic polymer wafers was visualized with 
fluorescence microscopy 24 h or 48 h post transfection (Figure 3.1). While a moderate 
amount of cells fluoresced green after transfection by polyplexes alone, none of the cells 
that were transfected with polyplex-loaded CMC, polyplex-loaded ALG wafers, or 




Figure 3.1 Representative fluorescence microscopy images of NIH/3T3 cells transfected 
by polyplex-loaded anionic polymer wafers in serum free medium. Polyplexes were 
prepared with N/P: 11. Cells were transfected for 4 h and fluorescently imaged after (A) 
24 h or (B) 48 h incubation. 
3.3.2 Transfection by polyplexes loaded into  nonionic polymer wafers 
Polyplexes (N/P: 8) were loaded into polymer wafers composed of the nonionic 
polymers PVA, HPC, PEO, or PVP. The transfection efficiency of NIH/3T3 cells in 
serum free or 10% serum containing media by these polyplex-loaded wafers was 
quantified by flow cytometry 24 h post transfection (Figure 3.2). In serum free medium, 
there was an overall shift of the cell populations into the GFP+ gate, especially when 







































































































Figure 3.2 Transfection efficiency of polyplex-loaded wafers in NIH/3T3 cells. 
Polyplexes were prepared with N/P: 8. Cells were transfected for 4 h and fixed after 24 h 
incubation with 2% paraformaldehyde. Representative flow cytometry dot plots of cells 
transfected in (A) serum free or (B) 10% serum containing media. (C) Percentage of 
GFP+ cells and (D) MFI of GFP+ cells after transfection in serum free medium. (E) 
Percentage of GFP+ cells and (F) MFI of GFP+ cells after transfection in 10% serum 
containing medium. Data are shown as mean ± SD (dots represent individual replicates) 
(n = 3 – 12).  ANOVA with Tukey HSD test (* p <0.05, **** p <0.0001 vs polyplex 
alone; # p <0.05, ## p <0.01, #### p <0.0001 vs polyplex-loaded PVA wafer). 
While it appeared that a slightly greater percentage of cells were GFP+ after 
transfection by polyplex-loaded PVA wafers (30.8% GFP+) as compared to cells 
transfected by polyplexes alone (25.4% GFP+), this result was not statistically significant 










































































































































































polyplex-loaded PVA wafers were also not statistically significantly different (p = 
0.5876) (Figure 3.2D). However, transfection by the other polyplex-loaded wafers was 
significantly worse. Only 4.2%, 0.7%, and 0.1% of cells were GFP+ after transfection by 
polyplex-loaded HPC, PEO, and PVP wafers, respectively (Figure 3.2C). In addition, the 
MFI of the few GFP+ cells transfected by these polyplex-loaded wafers was also quite 
low (Figure 3.2D).  
As expected, transfection efficiency was much worse in 10% serum containing 
medium. There was a much less dramatic shift of the cell populations into the GFP+ gate 
(Figure 3.2B). Only 1.7% of cells were GFP+ after transfection by polyplexes alone; 
however, 4.8% of the cells were GFP+ after transfection polyplex-loaded PVA wafers 
(Figure 3.2E). While this is still a low transfection efficiency, this increase was 
statistically significant (p < 0.0001). For cells transfected by the other polyplex-loaded 
wafers, less than 1% of cells were GFP+. While it appears that the MFI of GFP+ cells 
transfected by polyplex-loaded PVA wafers is greater than the MFI of GFP+ cells 
transfected by polyplexes alone, the large variability in the MFI of cells transfected by 
polyplexes alone renders this difference statistically insignificant (p = 0.1067) (Figure 
3.2F). 
Trying to increase the transfection efficiency, polyplexes were prepared with a higher 
N/P ratio (N/P: 11) and loaded into polymer wafers composed of PVA, HPC, PEO, or 
PVP. The transfection of NIH/3T3 cells in serum free medium by these polyplex-loaded 
wafers visualized with fluorescence microscopy 48 h post transfection (Figure 3.3). A 
moderate fraction of cells fluoresced green after transfection by polyplexes alone; 
however, it appeared that transfection by polyplex-loaded PVA wafers resulted in a 
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greater amount of green fluorescing cells. While some cells transfected by polyplex-
loaded HPC wafers expressed green fluorescence, transfection by polyplex-loaded PEO 
or PVP wafers resulted in little to no green fluorescing cells. 
 
Figure 3.3 Representative fluorescence microscopy images of NIH/3T3 cells transfected 
by polyplex-loaded wafers in serum free medium. Polyplexes were prepared with N/P: 
11. Cells were transfected for 4 h and fluorescently imaged after 48 h incubation. 
3.3.3 Transfection by polyplexes mixed in aqueous polymer solutions 
To examine how the physical form of the nonionic polymers effects the polyplex-
mediated transfection, polyplexes (N/P: 11) were mixed into aqueous solutions (2.5% 
w/v) of PVA, HPC, PEO, or PVP. The transfection of NIH/3T3 cells in serum free or 
10% serum containing media by polyplexes mixed in these solutions was visualized with 
fluorescence microscopy 48 h post transfection (Figure 3.4). In serum free medium, a 
similar trend was seen as cells transfected by polyplex-loaded wafers; however, for all of 
the polymers, fewer cells fluoresced green after transfection by polyplexes mixed in the 
polymer solutions (Figure 3.4A). In 10% serum containing medium, transfection by 
polyplexes mixed in the polymer solutions was poor (Figure 3.4B). While a few cells 





























transfection by polyplexes mixed in HPC, PEO, or PVP solution resulted in little to no 
green fluorescing cells. 
 
 
Figure 3.4 Representative fluorescence microscopy images of NIH/3T3 cells transfected 
by polyplexes mixed in polymer solutions in (A) serum free or (B) 10% serum containing 
media. Polyplexes were prepared with N/P: 11. Cells were transfected for 4 h and 
fluorescently imaged after 48 h incubation. 
3.3.4 Polyplexes delivered by different physical forms of PVA 
To examine how the physical form of PVA effects the polyplex-mediated 
transfection, polyplexes (N/P: 11) were delivered to NIH/3T3 cells in serum free or 10% 




























































with fluorescence microscopy 48 h post transfection (Figure 3.5). In serum free medium, 
many cells expressed green fluorescence after transfection by polyplex-loaded PVA 
wafers; however, fewer cells appeared to express green fluorescence after transfection by 
polyplexes mixed in PVA solution (Figure 3.5A). Adding polyplexes alone alongside a 
blank PVA wafer also transfected fewer cells than polyplex-loaded PVA wafers.  
 
 
Figure 3.5 Representative fluorescence microscopy images of NIH/3T3 cells transfected 
by polyplexes in different physical forms of PVA in (A) serum free or (B) 10% serum 
containing media. Polyplexes were prepared with N/P: 11. Cells were transfected for 4 h 

























































In 10% serum containing medium, the differences in transfection by polyplexes in 
different physical forms of PVA is even more obvious. Many cells brightly fluoresced 
green after transfection by polyplex-loaded PVA wafers (Figure 3.5B). In contrast, very 
few cells expressed green fluorescence after transfection by polyplexes alone, polyplexes 
mixed in PVA solution, or polyplexes alone alongside a blank PVA wafer. 
The quantification of transfection efficiency by flow cytometry (Figure 3.6) was in 
agreement with the fluorescence microscopy images. In addition to polyplex-loaded PVA 
wafers and polyplexes mixed in PVA solution, polyplex-loaded PVA wafers were 
reconstituted in serum free or 10% serum containing media prior to transfection. In serum 
free medium, there was an overall shift of the cell populations into the GFP+ gate; 
however, this shift was greater in cells transfected by polyplexes alone or polyplex-
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Figure 3.6 Transfection efficiency of polyplexes delivered by different physical forms of 
PVA in NIH/3T3 cells. Polyplexes were prepared with N/P: 11. Cells were transfected 
for 4 h and fixed after 48 h incubation with 2% paraformaldehyde. Representative flow 
cytometry dot plots of cells transfected in (A) serum free of (B) 10% serum containing 
media. (C) Percentage of GFP+ cells and (D) MFI of GFP+ cells after transfection in 
serum free medium. (E) Percentage of GFP+ cells and (F) MFI of GFP+ cells after 
transfection in 10% serum containing medium. Data are shown as mean ± SD (dots 
represent individual replicates) (n = 6 – 30). ANOVA with Tukey HSD test (* p <0.05, 
*** p <0.001, **** p <0.0001 vs polyplex alone; ### p <0.001, #### p <0.0001 vs 
polyplex-loaded PVA wafer).   
Approximately 30% of cells were GFP+ after transfection by polyplexes alone or 
polyplex-loaded PVA wafers; however, only 21.2% and 11.8% of cells were GFP+ after 

























































































































































PVA wafers, respectively (Figure 3.6C). Although the percentage of GFP+ cells 
transfected was similar, the MFI was lower in GFP+ cells transfected by polyplex-loaded 
PVA wafers was lower than GFP+ cells transfected by polyplexes alone (p < 0.0001) 
(Figure 3.6D).  
In 10% serum, transfection efficiency was significantly higher in cells transfected by 
polyplex-loaded PVA wafers. A very low percentage of cells transfected by polyplexes 
alone, polyplexes mixed in PVA solution, or reconstituted polyplex-loaded PVA wafers 
shifted into the GFP+ gate (Figure 3.6B). Strikingly, nearly 20% of cells were GFP+ after 
transfection by polyplex-loaded PVA wafers, as compared to only 2.2% GFP+ cells after 
transfection by polyplexes alone (Figure 3.6E). For a few experimental replicates, 
between 37-53% of the cells were GFP+ when transfected by polyplex-loaded PVA 
wafers. Interestingly, the high transfection efficiency was completely lost if the polyplex-
loaded PVA wafers were reconstituted in 10% serum containing medium prior to 
transfection. Only 1.1% of cells were GFP+ after transfection by reconstituted polyplex-
loaded PVA wafers. While there was a small increase in MFI of the GFP+ cells 
transfected by polyplex-loaded PVA wafers as compared to GFP+ cells transfected by 
polyplexes alone, this result was not statistically significant (p = 0.0582) (Figure 3.6F). 
3.3.5 Biocompatibility of polyplex-loaded polymer wafers 
The biocompatibility of blank wafers and polyplex-loaded wafers was evaluated by 
exposing NIH/3T3 cells to the wafers for 4 h in serum free or 10% serum containing 
media. Cell viability was measured after 24 h incubation by an MTT assay (Figure 3.7). 
In serum free medium, blank HPC, PEO, and PVP wafers displayed no cytotoxicity 
(Figure 3.7A). When polyplexes (N/P: 8) alone were given, cell viability decreased 
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31.4%. Polyplex-loaded HPC and polyplex-loaded PVP wafers were also relatively 
cytotoxic, as 48% and 67.3% of cells were killed, respectively. While exposure to blank 
PVA wafers resulted in a 22.5% reduction in cell viability, loading polyplexes (N/P: 8) 
into PVA wafers did not generate any additional toxicity. Polyplex-loaded PEO wafers 
were similarly nontoxic as the blank PEO wafers. Similar trends were seen in 10% serum 
medium with the exception of polyplexes (N/P: 8) alone, which did not display any 
cytotoxicity (Figure 3.7B). While there was an approximately 27% decrease in cell 
viabilities, there was again no difference between cells exposed to blank PVA and 
polyplex-loaded PVA wafers. 
 
Figure 3.7 NIH/3T3 cell viability after exposure to blank or polyplex-loaded wafers in 
(A) serum free or (B) 10% serum containing media. Polyplexes were prepared with N/P: 
8. Cells were exposed for 4 h and cell viability was measured by MTT assay after 24 h 
incubation. Data are shown as mean ± SD (n = 4 – 8).  
The biocompatibility of different physical forms of PVA was also evaluated. 
NIH/3T3 cells were exposed to the physical forms of PVA for 4 h in serum free or 10% 
serum containing media. Cell viability was measured after 24 h incubation by an MTT 
assay (Figure 3.8). In serum free medium, it was interesting to note that although blank 





















































reconstituted blank PVA wafers exhibited no toxicity (Figure 3.8A). While loading naked 
DNA into any of the physical forms of PVA did not increase toxicity, polyplex (N/P: 11)-
loaded PVA was more toxic than the different physical forms of blank PVA. This was 
especially true in polyplex-loaded PVA wafers, where only 22.2% of cells remained 
viable. In 10% serum, PVA solution and reconstituted PVA wafers were mostly nontoxic. 
Regardless of the cargo, over 90% of cells remained viable after exposure to these 
physical forms of PVA (Figure 3.8B). PVA wafers were less toxic in 10% serum, as 
73.8% and 63.0% of cells remained viable after exposure to blank PVA wafers and 
polyplex (N/P: 11)-loaded PVA wafers, respectively. 
 
Figure 3.8 NIH/3T3 cell viability after exposure to blank or polyplexes in different 
physical forms of PVA in (A) serum free or (B) 10% serum containing media. Polyplexes 
were prepared with N/P: 11. Cells were exposed for 4 h and cell viability was measured 
by MTT assay after 24 h incubation. Data are shown as mean ± SD (n = 4 – 12).   
3.3.6 Particle size of polyplexes released from nonionic polymer wafers  
The effective diameter of polyplexes (N/P: 8 or 11) alone or polyplexes released from 
PVA, HPC, PEO, or PVP wafers in serum free or 10% serum containing media was 
measured by DLS (Figure 3.9). As it was not possible to measure the effective diameter 





















































polyplexes released from the wafers were first measured at the 15 min timepoint. In 
serum free medium, polyplexes (N/P: 8) alone in buffer had initial effective diameter of 
285.5 nm and aggregated to 792.8 nm after 4 h (Fig. 9A). Polyplexes (N/P: 8) released 
from PEO wafers also aggregated over time, up to 1067.5 nm after 4 h. In contrast, 
polyplexes (N/P: 8) released from PVA wafers were more colloidally stable with an 
effective diameter of approximately 150 nm throughout the entire 4 h. There was a slight 
decrease in effective diameter of polyplexes (N/P: 8) released from HPC wafers (297.8 
nm at 15 min to 219.9 nm at 4 h) or PVP wafers (98.0 nm at 15 min to 78.5 nm at 4 h). 
Nearly identical trends were seen for polyplexes with N/P: 11 (Figure 3.9B). 
 
 
Figure 3.9 Size of polyplexes released from wafers in serum free medium with (A) N/P: 
8 or (B) N/P: 11. Size of polyplexes released from wafers in 10% serum containing 
medium with (C) N/P: 8 or (D) N/P: 11. Data are shown as effective diameter ± half 
width as measured by DLS. 
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In general, smaller effective diameters were measured in 10% serum (Figure 3.9C,D). 
This is partially due to the presence of the serum proteins forming particles 
approximately 19 nm in diameter, which skews the data smaller. Unlike in serum free 
medium, polyplexes (N/P: 8) alone in buffer were relatively colloidally stable, with an 
effective diameter of approximately 60-70 nm over the 4 h (Figure 3.9C). Polyplexes 
(N/P: 8) released from PVA wafers were similarly sized, with an effective diameter of 
approximately 65-80 nm over the 4 h. While colloidally stable, polyplexes (N/P: 8) 
released from HPC wafers were slightly larger (~105 nm) whereas polyplexes (N/P: 8) 
released from PVP wafers were slightly smaller (~20 nm) than polyplexes (N/P: 8) alone 
in buffer. Again, nearly identical trends were seen for polyplexes with N/P: 11 in 10% 
serum (Figure 3.9D). 
3.3.7 Particle size of polyplexes released from different physical forms of PVA 
The effective diameter of polyplexes (N/P: 11) alone or released from different 
physical forms of PVA in serum free or 10% serum containing media was measured by 
DLS (Figure 3.10). In serum free medium, there was little difference in effective diameter 
of polyplexes released from the PVA forms (Figure 3.10A). Polyplexes released from 
PVA wafers or reconstituted PVA wafers were approximately 150 nm at all time points. 
Polyplexes mixed with PVA solution initially had an effective diameter of 101.3 nm, but 
after 4 h had grown to 169.5 nm. In 10% serum, polyplexes alone and polyplexes 
released from PVA wafers were similar in size, approximately 80 nm at all time points 
(Figure 3.10B). Polyplexes released from reconstituted PVA wafers were slightly larger 
(~140 nm) whereas polyplexes mixed with PVA solution were slightly smaller (~40 nm). 
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Figure 3.10 Size of polyplexes released from different physical forms of PVA in (A) 
serum free or (B) 10% serum containing media. Polyplexes were prepared with N/P: 11. 
Data are shown as effective diameter ± half width as measured by DLS. 
3.4 Discussion 
In order for a nonviral gene delivery system to be a viable therapeutic agent, it must 
be able to transfect cells in the presence of serum [30]. The goal of this study is to use 
polymer wafers to improve efficiency of polyplex-mediated gene delivery in serum 
containing medium. We have previously demonstrated the ability of wafers composed of 
binary blends of CMC and ALG to preserve and improve the delivery of sublingual 
protein vaccines; however, it was quickly determined that these would be unsuitable for 
nonviral gene delivery. Even in serum-free medium, polyplexes loaded into CMC, ALG, 
or CMC:ALG (1:1) wafers were unable to transfect NIH/3T3 cells (Figure 3.1). CMC 
and ALG are both anionic polymers [99,106] and likely adsorbed onto the polyplexes, 
inhibiting their electrostatic attraction to the cell membrane. Therefore, we sought to 
prepare wafers comprised of nonionic polymers. Four nonionic polymers were chosen, 
PVA, HPC, PEO, and PVP, due their good water solubility and history of use as 
pharmaceutical excipients [84]. 
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The in vitro transfection experiments indicated PVA was vastly superior to HPC, 
PEO, or PVP for preparing wafers to improve polyplex-mediated gene delivery. In serum 
free medium, although polyplex-loaded PVA wafers elicited comparable transfection 
efficiency to polyplexes alone, they performed significantly better than polyplex-loaded 
HPC, PEO, or PVP wafers (Figure 3.2, Figure 3.3). The most outstanding benefit of PVA 
wafers was seen when cells were transfected in 10% serum containing medium. The 
transfection efficiency of polyplexes alone (and polyplex-loaded HPC, PEO, or PVP 
wafers) in 10% serum containing medium was very low (Figure 3.2E); however, 
transfection by PVA wafers loaded with polyplexes (N/P: 11) resulted in many GFP+ 
cells (Figure 3.5B, Figure 3.6E).  
A critical component of developing polyplex-loaded polymer wafers was to 
determine was the effect on the polyplex size following release from the wafers into 
serum free and 10% serum containing medium. As expected, polyplexes alone 
aggregated in serum free medium (Figure 3.9A,B). However, aggregation of polyplexes 
alone was not observed in 10% serum containing medium. Polyplexes released from PEO 
wafers in serum free medium aggregated even faster than polyplexes alone. Additionally, 
only polyplexes released from PEO wafers aggregated in 10% serum containing medium. 
PEGylated polyplexes have previously been shown to unpackage more easily than 
unmodified polyplexes. Incorporation of PEG into the core likely weakened the 
electrostatic interactions holding the polyplexes together [34]. Perhaps PEO, which is 
chemically identical to PEG but has a higher molecular weight, also disrupted the 
electrostatic interactions of our polyplexes. Polyplexes released from PVA, HPC, and 
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PVP wafers did not aggregate in serum free (Figure 3.9A,B) or 10% serum containing 
medium (Figure 3.9C,D). 
Taken together, these results suggest that polyplex size does not seem to correlate 
with transfection efficiency. In 10% serum, the size of polyplexes alone and polyplexes 
released from PVA wafers are nearly identical. However, the transfection efficiency by 
polyplex-loaded PVA wafers is much higher (Figure 3.5B, Figure 3.6E). Likewise, the 
size of polyplexes released from the different physical forms of PVA could not explain 
the observed differences in transfection efficiency (Figure 3.10). In serum free medium, 
the polyplexes released from the different physical forms of PVA were nearly identical at 
all time points. None of the released polyplexes from the different physical forms of PVA 
aggregated in 10% serum. Additionally, the differences in polyplex size did not correlate 
with transfection efficiency. 
When polyplexes were mixed into an aqueous solution of PVA, the transfection 
efficiency was diminished in both serum free and 10% serum containing medium (Figure 
3.5), revealing that the physical form of PVA is a critical factor in the enhancement of 
polyplex-mediated gene delivery. PVA is a linear, synthetic polymer that is frequently 
used in pharmaceutical sciences. The ability to form films, stabilize suspensions by 
increasing viscosity, bioadhesiveness, and high biocompatibility have made PVA one of 
the best known and commonly used excipients [123]. PEI-based polyplexes (and 
lipopolyplexes) released from microparticles were found to be colloidally stable and 
transfect cells with good efficiency in the presence of serum. Schulze et al. attributed this 
to the formation of a PVA ‘corona’ coating the polyplexes, shielding the positive surface 
charges, preventing aggregation and protein adsorption [37,38]. We speculate that a 
 71 
similar mechanism can explain why polyplex-loaded PVA wafers displayed high 
transfection efficiency in NIH/3T3 cells (Figure 3.5, Figure 3.6). However, the different 
physical forms may differ in the amount of PVA coating the polyplexes. When polyplex-
loaded PVA wafers are placed in media to transfect cells, they disintegrate over the 
course of 15-30 min. During this time, the polyplexes are released into media, likely with 
a relatively thin PVA coating because the bulk of the PVA remains in the disintegrating 
wafer. The thin coating may be enough to shield the polyplexes enough to prevent 
aggregation and protein adsorption but thin enough that the electrostatic attraction to cell 
membranes is still maintained. Mixing polyplexes into an aqueous PVA solution; 
however, might result in a much thicker PVA coating. This thicker coating may inhibit 
the polyplex attraction to cell membranes, resulting in reduced cellular uptake. The 30 
min incubation and vigorous vortex mixing that was done to reconstitute polyplex-loaded 
PVA wafers likely generated a similar PVA coating to polyplexes mixed in aqueous PVA 
solution. 
Although the different amounts of PVA coating did not have much effect on the 
polyplex size (Figure 3.10), it may have profound effects on the zeta potential. Schulze et 
al. also noted that the PVA corona greatly reduced the zeta potential of polyplexes. While 
freshly prepared polyplexes displayed positive zeta potential (approximately +20 to +25 
mV), polyplexes released from PVA microparticles showed negative zeta potential 
(approximately -10 to -20 mV) [37]. The zeta potential of our PEI/DNA polyplexes may 
have been similarly affected, with polyplexes mixed into PVA solution or released from 
reconstituted PVA wafers experiencing the greatest decrease in zeta potential. Zeta 
potential reduction may also explain why polyplex (N/P:11)-loaded PVA wafers 
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transfected cells with high efficiency in 10% serum containing medium (Figure 3.5B, 
Figure 3.6E), whereas polyplex (N/P: 8)-loaded PVA wafers did not (Figure 3.2E). In the 
absence of a PVA coating, polyplexes with the lower N/P ratio have a lower zeta 
potential. Even a minimal PVA coating may inhibit the electrostatic attraction of 
polyplexes (N/P: 8) to cell membranes. 
In addition to high transfection efficiency, biocompatibility of nonviral gene delivery 
systems is crucial. While the high cationic charge density of PEI is responsible for the 
electrostatically favorable interactions between PEI-based polyplexes and anionic cell 
membranes, the charge density can also irreversibly damage the cell membrane, inducing 
lysis or necrotic death [124]. Surprisingly, even blank PVA wafers were somewhat 
cytotoxic. Even though PVA is considered to have good biocompatibility [123], 
approximately 25% of cells were killed after 4 h exposure to blank PVA wafers in both 
serum free and 10% serum containing medium (Figure 3.7). In contrast, blank HPC, 
PEO, and PVP wafers display almost no toxicity. Even more confounding, blank PVA 
solution and blank reconstituted PVA wafers do not exhibit cytotoxicity (Figure 3.8). It 
appears that is not is not PVA itself, nor any potential contamination during the 
preparation of PVA wafers, but something about the physical form of the PVA wafers is 
responsible for the cytotoxicity. When PVA wafers are placed in media, they disintegrate 
over the course of 15-30 min, but the PVA does not completely dissolve. At the end of 
the 4 h transfection protocol, the media was removed by vacuum aspiration and the cells 
were washed with PBS. Perhaps during the aspiration, undissolved PVA particulates 
mechanically damaged the cells, resulting in toxicity. Although polyplexes alone and 
polyplex-loaded HPC and PVP wafers were more toxic than their blank counterparts, the 
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observation that polyplex-loaded PVA wafers are not more cytotoxic than blank PVA 
wafers in 10% serum containing medium is encouraging (Figure 3.8). If the aspiration-
induced mechanical cell damage is an artifact of the in vitro protocol, perhaps the 
polyplex-loaded PVA wafers would more biocompatible when tested in vivo. 
Taken together, these results demonstrate that PVA wafers are an effective delivery 
system to improve the in vitro transfection efficiency of polyplex-mediated gene delivery 
in the presence of serum. As PVA is known to have mucoadhesive properties [84], these 
wafers may be exceptionally suited for mucosal delivery of gene therapy. While we 
demonstrated high transfection efficiency using GFP as a reporter gene, future studies 
using these PVA wafers will deliver DNA vaccines. These vaccines could be delivered to 
the sublingual mucosa, or other targeted mucosal tissue, to generate robust cell-mediated 
and humoral immune responses.  
3.5 Conclusions 
We have prepared and loaded PEI/DNA polyplexes into polymer wafers consisting of 
various water-soluble polymers – CMC, ALG, PVA, HPC, PEO, and PVP – through a 
simple process. Polyplex-loaded PVA wafers transfected NIH/3T3 cells in vitro with high 
efficiency. While the transfection efficiency by polyplex-loaded PVA wafers was similar 
to polyplexes alone in serum free medium, the PVA wafers greatly enhanced the 
polyplex-mediated transfection efficiency in 10% serum containing medium. We also 
observed that the physical form of the PVA wafer is crucial for this enhancement. These 
findings established that the polyplex-loaded PVA wafers have the potential to improve 





Chapter 4 Synergistic Cancer Cell Killing by a Synthetic Membranolytic Polymer 
and Doxorubicin 
4.1 Introduction 
Cancer is the second leading cause of mortality globally and was responsible for 9.6 
million deaths in 2018 [125]. Doxorubicin (DOX) is one of the most effective 
chemotherapeutic agents and is used to treat many types of cancer, including cancers of 
the bladder, breast, stomach, lung, ovaries, thyroid, soft tissue sarcoma, multiple 
myeloma, and Hodgkin’s lymphoma [39]. DOX is an anthracycline that intercalates 
between nucleic acid base pairs, blocking the transcription and replication processes by 
inhibiting the synthesis of DNA and RNA in rapidly dividing cells [126]. DOX also 
inhibits the enzyme topoisomerase II, which prevents the resealing of DNA double 
helices and stops replication [127]. DOX can also generate free radicals that induce DNA 
and cell membrane damage, triggering apoptosis [39]. 
Despite the potency of DOX, many cancer cells develop multidrug resistance to DOX 
and other chemotherapeutic drugs. A number of mechanisms may elicit multidrug 
resistance, including the overexpression of membrane transporters such as P-glycoprotein 
and Multidrug Resistance-Associated Protein 1 (MRP1) which act as efflux pumps that 
pump chemotherapeutic drugs out of cancer cells [41]. To overcome the reduced drug 
uptake, higher drug dosage must be used. However, high DOX doses presents severe side 
effects such as cardiotoxicity and myelosuppression [128]. A number of nanocarriers 
have been developed to target DOX accumulation within tumors to reduce off target 
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toxicity, such as PEGylated liposomes (e.g. Doxil®) [128]; however, the issue of poor 
drug uptake remains. 
One class of anti-cancer agents that may overcome multidrug resistance are cationic 
macromolecules [11]. Inspired by naturally occurring antimicrobial peptides, such as 
defensins and cecropins [129], a number of amphipathic cationic peptides have been 
shown to effectively kill cancer cells [11]. These anticancer peptides are electrostatically 
attracted to negatively charged cancer cell membranes and disrupt the membranes by 
hydrophobic interactions, leading to increased membrane permeability and eventual cell 
lysis. Since the cytotoxic activity is directed to the cell membrane, these peptides can 
evade multidrug resistance mechanisms [11]. In addition, the increased membrane 
permeability can facilitate the uptake of traditional chemotherapeutic drugs. Anticancer 
peptides have been shown to increase cancer cell uptake of 5-fluorouracil, cytarabine, 
paclitaxel, epirubicin, and DOX [130–132]. 
Despite their promise, the high production cost and susceptibility to enzymatic 
degradation by serum proteases has limited the clinical application of these anticancer 
peptides [11]. In contrast, synthetic polymers can be designed to mimic the cationic 
amphipathic structure of anticancer peptides, while being easier to synthesize on a large 
scale and more resistant to proteolytic degradation. In addition, synthetic polymers are 
more chemically tunable and offer greater flexibility in terms of structure [11,133]. 
Several classes of polymers have been reported to induce membrane lysis, including 
polymethacrylates, polyacrylamides, polyethyleneimines (PEI), and polyamides [11,124]. 
Similar to anticancer peptides, these polymers can be used alone to kill cancer cells by 
membrane lysis or used in combination with chemotherapeutic agents to increase drug 
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uptake. A few synthetic polymers have been shown to enhance uptake of DOX by cancer 
cells, including branched PEI dendrimers [42], and poly(amido amine)-2,3-
dimethylmaleic monoamide (PAMAM-DMA) dendrimers [134]. 
The objective of the present study is to use a synthetic membranolytic polymer, poly 
(6-amino-1-hexyl methacrylate) (PAHM) to disrupt cancer cell membranes and to use 
PAHM in combination with DOX to kill cancer cells synergistically. Membrane 
disruption by PAHM and the increased uptake of DOX was examined using mouse breast 
cancer cells (EMT6) and human pancreatic cancer cells (AsPC-1). The cytotoxicity of 
PAHM and DOX to EMT6 and AsPC-1 was measured and the combination index (CI) 
and dose reduction index (DRI) of each of the PAHM and DOX combinations were 
quantified using the Chou-Talalay method [135]. Lastly, PAHM and DOX were used to 
kill EMT6 multicellular tumor spheroids. 
4.2 Materials and Methods 
4.2.1 Chemicals and reagents 
Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), 
Penicillin-Streptomycin (10,000 U/mL; 10,000 µg/mL), Dulbecco’s phosphate buffered 
saline (DPBS), phosphate buffered saline (PBS, pH 7.4), trypsin-EDTA (0.25%), trypan 
blue (0.4% solution, 0.85% NaCl), MTT (3-(4,5-dimethylthiazol- 2-yl)-2,5-
diphenyltetrazolium bromide) (MTT), dimethyl sulfoxide (DMSO), Live Cell Imaging 
Solution (LCIS), agarose, NucBlue Live ReadyProbes Reagent (Hoechst 33342), and 
NucGreen Dead 488 ReadyProbes Reagent (SYTOX Green) were purchased from 
Thermo Fisher Scientific (Waltham, MA). Propidium iodide (PI, 0.5 mg/mL in PBS) was 
purchased from BioLegend (San Diego, CA). Doxorubicin hydrochloride (European 
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Pharmacopoeia Reference Standard) was purchased from Sigma Aldrich (St. Louis, MO). 
Glass bottom microwell dishes were purchased from MatTek (Ashland, MA). 
4.2.2 Synthesis of poly (6-amino-1-hexyl methacrylate) (PAHM) 
N-(tert-butoxycarbonyl) aminohexyl methacrylate (tBocAHM) was synthesized as 
described by Zhu et al [136]. PAHM was synthesized via atom transfer radical 
polymerization (ATRP) of tBocAHM followed by deprotection of the tBoc side chains 
based on a method reported by Ji et al [137]. The polymer was characterized using 1H 
NMR and gel permeation chromatography (GPC) as described by Ji [138]. The PAHM 
used in the subsequent experiments had a number-average molecular weight (Mn) of 2.08 
× 104, Dispersity (Đ) of 1.26, and average degree of polymerization (DP) of 100. 
4.2.3 Cell culture 
Mouse mammary carcinoma cell line EMT6 and human pancreatic adenocarcinoma 
cell line AsPC-1 were obtained from ATCC. EMT6 or AsPC-1 cells were cultured in 
media consisting of RPMI 1640 medium with 2 g/L glucose, 2 mM L-glutamine, 2 g/L 
sodium bicarbonate, 10% heat inactivated fetal bovine serum (FBS), 100 U/mL 
penicillin, and 100 µg/mL streptomycin. EMT6 or AsPC-1 cells were cultured in tissue 
culture flasks and incubated in a humidified environment at 37ºC with 5% CO2. When 
cells reached ~80% confluency the culture medium was removed, cells were rinsed with 
DPBS, and 0.25% trypsin-EDTA was added for 5 min to detach cells from the flasks. 
Harvested cells were centrifuged at 200 x g for 5 min and supernatant was discarded. Cell 
pellets were resuspended in cell culture medium and a 100 µL aliquot was stained 1:1 
with trypan blue 0.4% solution and counted using a hemocytometer (Sigma-Aldrich, St. 
Louis, MO) and inverted microscope (Thermo Fisher Scientific, Waltham, MA). Cell 
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suspensions were split 1:3 to 1:6 to continue culture or diluted to the appropriate seeding 
density for subsequent experiments. 
4.2.4 Propidium iodide (PI) staining 
Cell membrane disruption by PAHM was visualized by staining cells with PI. EMT6 
or AsPC-1 cell suspensions were diluted to density of 50,000 cells/mL in cell culture 
media and were plated in glass bottom microwell dishes (50,000 cells/dish). Cells were 
incubated in a humidified environment at 37ºC with 5% CO2 overnight (~20 h). Culture 
media was removed, cells were washed twice with 1 mL PBS, and replaced with 1 mL 
live cell imaging solution (LCIS). PI stain was prepared by diluting PI stock solution (0.5 
mg/mL) to 40 µM in LCIS. Cells were stained with 4 µM PI by adding 110 µL PI stain 
(40 µM) to each dish. PAHM was dissolved in LCIS at varying concentration and 100 µL 
was added to each dish to give final concentrations of 0, 10, 20, 30, 40, 50, or 75 µg/mL.  
Phase contrast and fluorescent images of EMT6 cells were acquired with a Nikon 
Eclipse Ti-E inverted microscope equipped with a Nikon CFI Plan Apochromat Lambda 
40XC/0.95 NA objective and an Andor Zyla sCMOS camera. PI was visualized using an 
excitation wavelength of 515 ± 30 nm and emission wavelength of 590 ± 45 nm. An 
exposure time of 27 ms was chosen to minimize autofluorescence. EMT6 cells were kept 
in an environmental chamber at 37ºC with 5% CO2 and imaged continuously for 30 min. 
Images were analyzed in ImageJ. 
Phase contrast and fluorescent images of AsPC-1 cells were acquired with an 
Olympus IX70 inverted microscope equipped with an Olympus plan fluorite 20XPH/0.45 
NA objective, an Olympus DP72 camera, and an X-Cite 120 Wide-Field Fluorescence 
Microscope Excitation Light Source (Excelitas Technologies, Waltham, MA). PI was 
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visualized using an excitation wavelength of 535 ± 50 nm and emission wavelength of 
610 ± 75 nm. An exposure time of 20 ms was chosen to minimize autofluorescnce. 
AsPC-1 cells were kept under ambient conditions and imaged after 30 min exposure to 
PAHM. 
4.2.5 Cellular uptake of DOX 
EMT6 or AsPC-1 cell suspensions were diluted to density of 50,000 cells/mL in cell 
culture media and were plated in glass bottom microwell dishes (100,000 cells/dish). 
Cells were incubated in a humidified environment at 37ºC with 5% CO2 overnight (~20 
h). Culture media was removed, cells were washed twice with 1 mL PBS, and replaced 
with 2 mL live cell imaging solution (LCIS). Cell nuclei were stained with Hoechst 
33342 by adding 2 drops of NucBlue Live ReadyProbes Reagent to each dish followed 
by incubation in a humidified environment at 37ºC with 5% CO2 for 20 min. DOX was 
dissolved in deoinized water at concentration of 5 mg/mL, diluted in LCIS, and 100 µL 
was added to each dish to give final concentrations of 0, 5, or 10 µg/mL DOX. PAHM 
was dissolved in LCIS at varying concentrations and 100 µL was added to each dish to 
give final concentrations of 0, 5, or 10 µg/mL PAHM. After incubating in humidified 
environment at 37ºC with 5% CO2 for 15 min, media containing DOX and PAHM were 
removed, cells were washed twice with 1 mL DPBS, and replaced with 2 mL fresh LCIS. 
Phase contrast and fluorescent images of EMT6 or AsPC-1 cells were acquired with 
an Olympus IX70 inverted microscope equipped with an Olympus plan fluorite 
20XPH/0.45 NA objective, an Olympus DP72 camera, and an X-Cite 120 Wide-Field 
Fluorescence Microscope Excitation Light Source (Excelitas Technologies, Waltham, 
MA). Hoechst 33342-stained cell nuclei were visualized using an excitation wavelength 
 80 
of 350 ± 50 nm and emission wavelength of 460 ± 50 nm. Exposure times of 2 ms 
(EMT6 cells) or 10 ms (AsPC-1 cells) were chosen to minimize autofluorescence. DOX 
was visualized using an excitation wavelength of 535 ± 50 nm and emission wavelength 
of 610 ± 75 nm. Exposure times of 20 ms (EMT6 cells) or 100 ms (AsPC-1) cells was 
chosen to minimize autofluorescence. Images were analyzed in ImageJ. 
4.2.6 Cytotoxicity of DOX and PAHM in 2D monolayer culture 
EMT6 or AsPC-1 cell suspensions were diluted to 50,000 cells/mL in phenol red free 
cell culture media and were plated in 96-well plates (5,000 cells/well). Cells were 
incubated in a humidified environment at 37ºC with 5% CO2 overnight (~20 h). DOX 
was dissolved in deionized water at concentration of 5 mg/mL and diluted in phenol red 
free cell culture media at varying concentrations. PAHM was dissolved directly in phenol 
red free cell culture media at varying concentrations. Cell culture media was removed 
from EMT6 or AsPC-1 cells and replaced with 100 µL media containing DOX, PAHM, 
or combinations of DOX and PAHM at varying concentrations. After incubation in a 
humidified environment at 37ºC with 5% CO2 for 24 or 48 h, media containing DOX and 
PAHM were removed and replaced with 100 µL fresh phenol red free cell culture media. 
Cell viability was evaluated using an MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay [122]. To each well, 10 µL MTT solution (5 mg/mL in 
DPBS) was added. After 4 h incubation in a humidified environment at 37ºC with 5% 
CO2, 85 µL medium was removed from each well. Formazan crystals were dissolved in 
50 µL DMSO and absorbance was measured at 540 nm and corrected for blank media 
background using a BioTek Cytation 3 Cell Imaging Multi-Mode Reader BioTek 
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Instruments, Winooski, VT). Cell viability was determined by normalizing by the 
absorbance of untreated cells. 
4.2.7 COMPUSYN modeling of drug synergy 
For each combination of DOX and PAHM, the combination index (CI) and dose 
reduction index (DRI) were calculated by the Chou-Talalay method with the CompuSyn 
software program (ComboSyn Inc., Paramus, NJ) [135]. Input parameters were the dose 
of each treatment (alone or in combination) and the corresponding fractional affect (Fa) – 
the fraction of cell growth inhibited by a particular dose, calculated as Fa = (100% - cell 
viability / 100%). The dose-effect relationship for DOX or PAHM and their combinations 
are described by the Median-Effect Equation Fa/Fu = (D/Dm)m, where Fu is the 
unaffected fraction of cell growth (Fu = 1 – Fa), D is the dose required to produce Fa, Dm 
is the median-effect dose (i.e. IC50), and m is the dynamic order of the curve. Using these 
parameters, the CI and DRI can be calculated. The CI value is dimensionless 
quantification of drug interaction, calculated as CI = (D)1/(Dx)1 + (D)2/(Dx)2, where (Dx)1 
is the dose of single drug D1 (i.e. DOX concentration) “alone” that inhibits cell growth by 
x%, (Dx)2 is the dose of a second drug D2 (i.e. PAHM concentration) “alone” that inhibits 
cell growth by x%, and (D)1 and (D)2 are the doses “in combination” that also inhibit cell 
growth by x%. CI = 1 indicates an additive effect; CI < 1 indicates a synergistic effect; CI 
> 1 indicates an antagonistic effect. The DRI is a measure of how much the dose of each 
drug can be reduced if used in combination at a given Fa as compared to the dose of each 
drug alone, calculated as (DRI)1 = (Dx)1/(D)1 and (DRI)2 = (Dx)2/(D)2. DRI = 1 indicates 
no dose reduction; DRI > 1 indicates favorable dose reduction, DRI < 1 indicates 
unfavorable dose reduction. 
 82 
4.2.8 Formation of EMT6 tumor spheroids 
Multicellular 3D tumor spheroids were formed as described previously [139]. 
Agarose was dissolved in phenol red free RPMI 1640 (15 mg/mL) and sterilized by 
autoclaving (121ºC, 15 psi) for 20 min. Sterile agarose solution was placed in an 85ºC 
water bath inside a tissue culture hood. The bottom of 96-well plates was coated with 60 
µL/well warm agarose solution. After allowing the agarose solutions to solidify, the 
coated plates were wrapped in aluminum foil and stored in a tissue culture hood 
overnight. EMT6 cell suspensions were diluted to 15,000 cells/mL in phenol red free cell 
culture medium and were plated in agarose-coated 96-well plates (3,000 cells/well). Cells 
were incubated in a humidified environment at 37ºC with 5% CO2 to allow spheroids to 
form. Phase contrast images of the spheroids were acquired with an Olympus IX70 
inverted microscope equipped with an Olympus plan 10X/0.25 NA objective and an 
Olympus DP72 camera. Images were analyzed and the initial spheroid area was 
quantified using ImageJ. 
4.2.9 Cytotoxicity of DOX and PAHM in 3D tumor spheroids 
DOX was dissolved in deionized water at concentration of 5 mg/mL and diluted in 
phenol red free cell culture media at varying concentrations. PAHM was dissolved 
directly in phenol red free cell culture media at varying concentrations. From each 
spheroid, 100 µL cell culture medium was removed and replaced with 100 µL media 
containing DOX, PAHM, or combinations of DOX and PAHM at varying concentrations. 
Spheroids were incubated for 3 days in an environment at 37ºC with 5% CO2. Each day, 
phase contrast images of the spheroids were acquired and quantified as described above. 
Spheroid growth was determined by normalizing by the initial spheroid area. 
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4.2.10 Statistical analysis 
ANOVA and Tukey HSD test for multiple comparisons were to determine the 
significance of differences in onset time of membrane disruption by different PAHM 
concentrations, differences in fluorescence intensity of intracellular DOX, and 
differences in cell viability between different treatment groups. All analyses were 
performed using GraphPad prism, version 9.0.0 (GraphPad software Inc., San Diego, 
California, USA). 
4.3 Results 
4.3.1 Cell membrane disruption by PAHM 
The disruption of EMT6 cell membranes by PAHM was visualized by intracellular 
staining by PI, a membrane impermeable dye that enters a cell through disrupted 
membrane and binds to DNA, resulting in a 20- to 30-fold increase in fluorescence 
intensity [140]. After exposure to 10 – 75 μg/mL of PAHM, PI fluorescence signal 
appeared inside many EMT6 cells within minutes, indicating that the cell membrane was 
permeabilized (Figure 4.1A). The percentage of PI+ cells over time was dependent on 
PAHM concentration. For cells treated with a high dose of PAHM (≥40 µg/mL), 100% 
became PI+ within 5 min; however, lower PAHM doses (10 – 30 µg/mL) only resulted in 
76 – 86% PI+ cells even after 30 min (Figure 4.1B). The onset time of membrane 
disruption correlated strongly with PAHM concentration. Lower PAHM doses (10 – 30 
µg/mL) did not cause membrane disruption until approximately 5 min later, whereas high 
PAHM doses (≥40 µg/mL) shortened the onset time of membrane disruption to about 1 – 
2 min (Figure 4.1C). Similar observation was made on PAHM-treated AsPC-1 cells as 













































Figure 4.1 Visualization of disruption of EMT6 membranes by PAHM. (A) 
Representative time-lapse fluorescence microscopy images of PAHM-treated EMT6 cells 
stained with PI. (B) Percentage of PI+ cells over time (n = 42 – 90). (C) Onset time of 
membrane disruption. Data are shown as mean ± SEM (n = 36 – 90). ANOVA with 
Tukey HSD test (**** p <0.0001 vs 10 µg/mL PAHM, #### p <0.0001 vs 20 µg/mL 
PAHM, &&&& p <0.0001 vs 30 µg/mL PAHM). 
 
Figure 4.2 Visualization of disruption of AsPC-1 membranes by PAHM. Representative 
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4.3.2 PAHM-mediated membrane disruption leads to enhanced DOX uptake 
To examine the impact of PAHM treatment on the intracellular uptake of DOX, 
EMT6 and AsPC-1 cells were exposed to DOX at 5 and 10 µg/mL in the presence or 
absence of equal mass concentrations of PAHM and visualized with fluorescence 





































































Figure 4.3 Membrane disruption by PAHM leads to increased cellular uptake of DOX. 
Representative fluorescence microscopy images of (A) EMT6 cells and (B) AsPC-1 cells. 
Quantification of DOX fluorescence intensity in (C) EMT6 cells and (D) AsPC-1 cells. 
Data are shown as mean ± SEM (C) (n = 183 – 499) (D) (n = 109 – 160). ANOVA with 
Tukey HSD test (**** p < 0.0001, ns: not significant). 
These doses of DOX and PAHM were chosen because they were low enough not to 
cause massive cell death in 15 min, which would otherwise make observation of DOX 
uptake impossible. The microscopy images and the quantification of the intracellular 
DOX fluorescence intensity in both cell lines show that DOX alone at 5 and 10 µg/mL 
had very low level of intracellular uptake, yet 5 µg/mL of PAHM led to a small but 
significant increase in DOX uptake in EMT6 cells (Figure 4.3C). Notably, the treatment 
with 10 µg/mL of PAHM led to a 2.7-fold increase in DOX uptake in EMT6 cells (p 
<0.0001) (Figure 4.3C) and a 3.0-fold increase in DOX uptake in AsPC-1 cells (p 
<0.0001) (Figure 4.3D). 
4.3.3 Combination of DOX and PAHM kills cells synergistically 
 To study the synergistic cytotoxicity of DOX and PAHM, EMT6 cells were exposed 
to DOX or PAHM alone (Figure 4.4A) or DOX and PAHM at constant ratios of 1:100 or 
1:50 (Figure 4.4B). The dose-effect curves were fit with the median-effect equation: fa/fu 
= (D/Dm)m, where D is the dose, Dm is the dose to produce median effect (i.e. IC50), fa 
C D













DOX + PAHM (1:1)
ns
✱✱✱✱

















is the fraction affected by dose D, fu is the unaffected fraction, and m depicts the shape of 
the dose-effect curve: For DOX or PAHM alone, the Dm were 0.3 µg/mL and 11.7 
µg/mL, respectively. The 1:100 DOX and PAHM combination displayed a similar dose-
effect curve to PAHM alone, with Dm = 13.1 µg/mL. In contrast, the 1:50 DOX and 
PAHM combination resulted in greater cytotoxicity as indicated by the lower Dm of 3.7 
µg/mL. Using these parameters, the CI of both 1:100 and 1:50 combinations were 
modelled across all Fa (Figure 4.4C,D). At lower Fa (≤0.65) the model of the 1:100 
combination of DOX and PAHM appears to be antagonistic, but the CI decreases with Fa 
(Figure 4.4C). In contrast, at high Fa (≥0.8) the 1:100 combination shows synergism 
between DOX and PAHM as indicated by the CI ≤0.87. The 1:100 experimentally 
calculated CI are in good agreement with the model, as all but one of the 1:100 
combinations with Fa ≥0.85 had experimentally calculated CI ≤0.89. The 1:50 
combination displays much greater synergism between DOX and PAHM. The model 
shows that only for Fa ≥0.3, the 1:50 combination of DOX and PAHM are synergistic 
with CI ≤0.88 (Figure 4.4D). At high Fa (≥0.85), the 1:50 combination is strongly 
synergistic as indicated by CI ≤0.28. The experimentally calculated CI also show that the 
1:50 combination of DOX and PAHM is synergistic across a wide range of Fa. All but 
one of the 1:50 combinations was synergistic with CI ≤0.73. At very high Fa (≥0.97), the 




Figure 4.4 DOX and PAHM kill EMT6 cells synergistically. (A) Cell viability of EMT6 
cells after 24 h exposure to DOX or PAHM alone. (B) Cell viability of EMT6 cells after 
24 h exposure to DOX and PAHM. Data are shown as mean ± SD (A) (n = 6 – 30) (B) (n 
= 6 – 12). Data fit with median-effect equation [135]. (C,D) Combination index analysis 
(CI <1, = 0.9 - 1 (dashed lines), >1 indicates synergism, nearly additive effect, and 
antagonism, respectively). Error bars indicate 95% confidence intervals for CI values 
based on sequential deletion analysis [135]. (E,F) Dose reduction index analysis (DRI <1, 
=1 (dashed line), >1 indicates unfavorable dose reduction, no dose reduction, and 
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The DRI of both 1:100 and 1:50 combinations were similarly modelled across all Fa 
(Figure 4.4E,F). For the 1:100 combination, the DOX DRI increases with Fa while the 
PAHM DRI is approximately 1 for a majority of Fa, suggesting the DOX benefits more 
from the 1:100 combination with PAHM (Figure 4.4E). At high Fa (≥0.85) the DOX DRI 
were greater than 17.5 and 15.2 for the model and experimentally calculated DRI, 
respectively, which indicates that the DOX dose can be significantly reduced when 
combined with PAHM (1:100) to kill a high percentage of EMT6 cells. The DOX DRI 
from the 1:50 combination similarly increases with Fa but the PAHM DRI is 
approximately 2 for most Fa (Figure 4.4F). Thus, PAHM benefits slightly from the 
combination with DOX. In contrast, the DOX dose can be significantly reduced, 
especially at high Fa (≥0.85) where the DOX DRI were greater than 26.1 and 24.9 for the 
model and experimentally calculated DRI, respectively. 
The synergistic killing of AsPC-1 cells by DOX and PAHM to AsPC-1 cells was also 
demonstrated. AsPC-1 were exposed to DOX or PAHM alone (Figure 4.5A) or DOX and 
PAHM at a constant ratio of 1:1 (Figure 4.5B). For DOX or PAHM alone, the Dm were 
22.0 µg/mL and 8.3 µg/mL, respectively. The 1:1 combination of DOX and PAHM was 
more cytotoxic than either treatment alone, with a Dm of 7.9 µg/mL. The CI and DRI for 
the 1:1 DOX and PAHM combination were also modelled across all Fa (Figure 4.5C,D). 
DOX and PAHM appear to be synergistic at Fa ≥0.35 as all CI calculated by the model 
were ≤0.88 (Figure 4.5C). The model is in good agreement with the experimentally 
calculated CI, a majority of which were ≤0.86 for Fa ≥0.43. Similar to the EMT6 cells, 
AsPC-1 cells can be killed by reduced doses of DOX and PAHM when they are used 
together. Most of the PAHM DRI were approximately 2 and the DOX DRI increases with 
 91 
Fa (Figure 4.5D). At high Fa (≥0.85), DOX benefits greatly by the combination with 
PAHM as the DOX DRI were greater than 53.7 and 51.3 for the model and 
experimentally calculated DRI, respectively. 
 
Figure 4.5 DOX and PAHM kill AsPC-1 cells synergistically. (A) Cell viability of 
AsPC-1 cells after 24 h exposure to DOX or PAHM alone. (B) Cell viability of AsPC-1 
cells after 24 h exposure to DOX and PAHM. Data are shown as mean ± SD (A) (n = 6 – 
30) (B) (n = 6 – 18), Data fit with median-effect equation [135]. (C) Combination index 
analysis (CI <1, = 0.9 – 1 (dashed lines), >1 indicates synergism, nearly additive effect, 
and antagonism, respectively). Error bars indicate 95% confidence intervals for CI values 
based on sequential deletion analysis [135]. (E) Dose reduction index analysis (DRI <1, 
=1 (dashed line), >1 indicates unfavorable dose reduction, no dose reduction, and 
favorable dose reduction, respectively). 
4.3.4 Synergistic cytotoxicity dependent on PAHM concentration 
To further investigate the synergistic cytotoxicity, EMT6 cells were exposed to non-
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with PAHM resulted to increased cell death (Figure 4.6A). At low doses of DOX (0.1 – 1 
µg/mL), the addition of low doses of PAHM (1 – 10 µg/mL) led to a slight increase in 
cell killing over DOX alone. At higher doses of DOX (5 – 40 µg/mL), the addition of 1 – 
10 µg/mL PAHM had little effect. However, the addition of 20 – 40 µg/mL PAHM 
resulted in a much greater reduction in cell viability across all DOX doses. 
The CI follow a similar trend to the cell viability data (Figure 4.6B). For 
combinations of low DOX (0.1 – 1 µg/mL) and low PAHM (1 – 10 µg/mL) doses the CI 
were near or slightly below 1, indicating that these combinations were nearly additive or 
slightly synergistic. For high DOX (5 – 40 µg/mL) and low PAHM (1 – 10 µg/mL) doses 
the CI were all ≥1.16, indicating that these combinations were antagonistic. At high 
PAHM doses (20 – 40 µg/mL) all but one combination were synergistic with CI ≤0.76. 
The DOX DRI follow the same trend as the cell viability and CI data. The majority of 
the DOX DRI were greater than 1 (Figure 4.6C), indicating that the DOX dose can be 
reduced when used in combination with PAHM. The DOX DRI were also much greater 
when 20 – 40 µg/mL PAHM was added. Only the antagonistic combinations of high 
DOX (5 – 40 µg/mL) and low PAHM (1 – 10 µg/mL) gave DOX DRI <1. The PAHM 
DRI tends to increase with Fa and all but three of the PAHM DRI were >1 (Figure 4.6D), 
indicating that the PAHM can also be reduced when used in combination with PAHM. 
The PAHM DRI tends to decrease with PAHM concentration, suggesting that the lower 
PAHM doses benefit more from the combination with DOX. 
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Figure 4.6 Synergistic killing of EMT6 cells is dependent on PAHM concentration. (A) 
Cell viability of EMT6 cells after 24 h exposure to DOX and PAHM. Data are shown as 
mean ± SD (n = 6 – 30). ANOVA with Tukey HSD test (* p <0.05 vs DOX only). (B) 
Combination index analysis (CI <1, = 0.9 – 1 (dashed lines), >1 indicates synergism, 
nearly additive effect, and antagonism, respectively). Dose reduction index analysis for 
(C) DOX and (D) PAHM (DRI <1, =1 (dashed line), >1 indicates unfavorable dose 
reduction, no dose reduction, and favorable dose reduction, respectively). 
AsPC-1 cells were also exposed to non-constant ratios of DOX and PAHM for 24 h. 
Similar to EMT6 cells, the viability of AsPC-1 cells was greatly reduced when combining 
DOX with 5 – 40 µg/mL PAHM (Figure 4.7A). However, the addition of 1 µg/mL 






















































































PAHM did not appear to kill more cells than DOX alone. The CI and DRI for each DOX 
and PAHM combination were also calculated to examine the synergistic killing of AsPC-
1 cells.  
 
Figure 4.7 Synergistic killing of AsPC-1 cells is dependent on PAHM concentration. (A) 
Cell viability of AsPC-1 cells after 24 h exposure to DOX and PAHM. Data are shown as 
mean ± SD (n = 6 – 30). ANOVA with Tukey HSD test (* p <0.05 vs DOX only). (B) 
Combination index analysis (CI <1, = 0.9 – 1 (dashed lines), >1 indicates synergism, 
nearly additive effect, and antagonism, respectively). Dose reduction index analysis for 
(C) DOX and (D) PAHM (DRI <1, =1 (dashed line), >1 indicates unfavorable dose 
reduction, no dose reduction, and favorable dose reduction, respectively). 













































































































As seen in Figure 4.7B, the CI tends to decrease with Fa. While the combinations 
with 1 µg/mL PAHM were antagonistic with CI ≥1.37, all combinations with 5 – 20 
µg/mL PAHM were synergistic with CI ≤0.87. The DOX DRI follows a similar trend to 
the CI (Figure 4.7C). The DOX DRI tends to increase with Fa. While the DOX DRI are 
all <1 for 1 µg/mL PAHM, all combinations with 5 – 40 µg/mL PAHM gave DOX DRI 
>1. For 20 – 40 µg/mL PAHM, the DOX DRI was between 27.5 and 21414, indicating 
that the DOX dose can greatly be reduced when combined with PAHM. The PAHM DRI 
tends to decrease with PAHM concentration; however, for all combinations with 1 – 10 
µg/mL PAHM and a majority of combinations with 20 – 40 µg/mL PAHM the PAHM 
DRI was >1 (Figure 4.7D).  
4.3.5 Combination of DOX and PAHM shrinks 3D multicellular tumor spheroids 
EMT6 multicellular tumor spheroids were exposed to DOX and PAHM separately, or 
in combination for day. At 1-day intervals, the tumor spheroids were imaged (Fig. 4.8A-
C) and their size was measured (Fig 4.8D). The growth of the tumor spheroids was 
slowed, or in some cases inhibited, by PAHM treatment. Spheroids treated with 30 - 100 
µg/mL of PAHM remained the same size over the 3 days. DOX treatment, however, was 
able to shrink the tumor spheroids. Spheroids treated with 0.6 - 2 µg/mL of DOX 
decreased in size over the 3 days. Perhaps most encouraging, most combinations of DOX 
and PAHM were more effective than either treatment alone. The greatest reduction in 
size was seen in tumor spheroids treated with 0.6 µg/mL of DOX and 30 µg/mL of 
























Figure 4.8 Combination of DOX and 
PAHM shrinks EMT6 tumor spheroids. 
Representative microscopy images of 
EMT6 spheroids treated with (A) DOX 
alone (B) PAHM alone or (C) 
combination of DOX and PAHM. (D) 
Normalized area of treated EMT6 
spheroids over time. Data are shown as 
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4.4 Discussion 
Most anticancer polymers (and peptides) are cationic amphipathic molecules that 
cause death by disrupting the cell membrane integrity [11]. Anticancer polymers first 
bind to highly negatively charged cancer cell membranes via electrostatic interactions, 
followed by disruption to the cell membrane by hydrophobic interactions [43]. While the 
exact mechanism of these hydrophobic interactions is not fully understood, various 
mechanisms have been proposed to describe the membrane disruption, including the 
barrel-stave model, toroidal model, carpet model, and detergent model [11]. The cationic 
amphipathic structure of PAHM is similarly capable of disrupting cancer cell membranes. 
Cationic primary amines in the side chain allow PAHM to bind to the anionic cell surface 
and the hydrophobic components can destabilize the membrane. PAHM-mediated 
membrane disruption occurs very quickly. PI staining revealed that EMT6 cell 
membranes were disrupted within 2 minutes after treatment with high PAHM 
concentration (50 - 75 µg/mL) (Figure 4.1). However, membrane disruption was 
concentration dependent. At lower PAHM concentration (10 - 30 µg/mL), not all EMT6 
cells were PI+ and the onset time of membrane disruption was longer (~6 -7 min). This 
membrane disruption eventually leads to membrane lysis, allowing PAHM alone to 
effectively kill both EMT6 cells (Figure 4.4A) and AsPC-1 cells (Figure 4.5A). 
In addition to its inherent cytotoxicity, PAHM also greatly enhances the anticancer 
activity of DOX. DOX kills cells by inducing DNA damage through topoisomerase II 
inhibition and free radical generation [39,126,127]. However, many cancer cells have 
developed resistance mechanisms that render DOX ineffective, including the 
overexpression of efflux pumps that pump the drug out of cell. PAHM-mediated 
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membrane disruption can overcome this resistance mechanism [41]. Pores in the cell 
membrane allow DOX to freely enter the cell faster than the efflux pumps can remove it, 
resulting in increased intracellular DOX accumulation (Figure 4.3). Thus, DOX can more 
effectively kill cells. In fact, DOX and PAHM synergistically kill both EMT6 cells 
(Figure 4.4C,D, Figure 4.6B) and AsPC-1 cells (Figure 4.5C, Figure 4.7B). However, this 
synergy was dependent on PAHM concentration. The 1:100 combinations of DOX and 
PAHM were much less synergistic than the 1:50 combinations, where twice as much 
PAHM was added (Figure 4.4C,D). This was further examined by combinations with 
non-constant ratio of DOX and PAHM. At low PAHM dose (≤10 µg/mL), DOX and 
PAHM did not synergistically kill EMT6 cells; however, higher PAHM doses (20 - 40 
µg/mL PAHM) did display synergy (Figure 4.6B). Similar trends were seen in AsPC-1 
cells treated by combinations with non-constant ratio of DOX and PAHM (Figure 4.7B). 
It appears that there is a threshold PAHM concentration that is required to induce enough 
membrane disruption for enough DOX to accumulate to kill cells synergistically. 
However, many of the combinations that did not display synergy still induced cell death 
in a dose-sparing manner. The DRI for nearly all tested combinations were greater than 1 
(Figure 4.4E,F, Figure 4.5D, Figure 4.6C,D, Figure 4.7C,D), indicating that lower doses 
of DOX and PAHM can be used while maintaining the same cytotoxic effect. This dose 
reduction may also translate into clinical benefits including less toxic side effects, less 
cost, and higher patient compliance. 
Despite the remarkable synergistic cytotoxicity of DOX and PAHM to AsPC-1 and 
EMT6 cells, monolayer cell culture assays have some limitations in their ability to predict 
the efficacy of anticancer agents in vivo. More specifically, these assays do not 
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recapitulate cell-cell and cell-extracellular matrix interactions exhibited in tumors [139]. 
In contrast, multicellular tumor spheroids are a better in vitro model because cell-cell 
interactions can be established. Additionally, the multicellular spheroids contain regions 
of peripheral cell proliferation (outer region) and nutrient deficient hypoxia regions 
(core), which is more similar to tumor structure in vivo [141]. To further test the toxicity 
of DOX and PAHM, we formed multicellular tumor spheroids from EMT6 cells. When 
used separately, both DOX and PAHM reduced the size of the EMT6 spheroids as 
compared to the untreated controls (Figure 4.8A,B). Although PAHM appears to only 
slow spheroid growth, spheroids treated with ≥0.6 µg/mL of DOX shrunk in size after 3 
days. The combination of DOX and PAHM is even more effective, especially for the 
lower dose combinations (Figure 4.8D). In addition to differences in size, the mechanism 
of cell death appears to differ in spheroid treated with DOX or PAHM. Spheroids treated 
with PAHM alone (especially high concentrations of PAHM) released a lot of cellular 
debris, indicative of cell lysis (Figure 4.8B); however, spheroid treated with DOX (which 
induces apoptotic cell death [39]) did not release debris (Figure 4.8A). Spheroids treated 
with combinations of DOX and PAHM also released a lot of cellular debris (Figure 
4.8C). The combination and cell lysis and apoptotic cell death may kill tumor cells more 
effectively. 
Taken together, our results suggest that a synthetic membranolytic polymer, PAHM, 
can be used in combination with DOX to synergistically kill cancer cells. Future studies 
will test to ability of PAHM to synergize with other chemotherapy drugs. While the 
ability of the PAHM/DOX combinations to shrink multicellular tumor spheroids is 
encouraging, the efficacy of the combination therapy will need to be validated in 
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appropriate in vivo tumor models. Another future opportunity co-encapsulation and 
targeted delivery of both PAHM and DOX to tumors. 
4.5 Conclusions 
We have demonstrated that a synthetic membranolytic polymer, PAHM, when 
combined with DOX, led to enhanced killing of mouse breast cancer cells and human 
pancreatic cancer cells. PAHM-mediated membrane disruption led to increased 
intracellular accumulation of DOX. Nearly all tested combinations of PAHM and DOX 
caused cancer cell death in a dose-sparing manner, and combinations with sufficient 
PAHM concentration killed cells synergistically. Combination of PAHM and DOX also 
shrunk EMT6 multicellular tumor spheroids. These findings PAHM has the potential to 
improve the ability of chemotherapeutic drugs to treat multidrug resistant cancer cells. 
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Chapter 5 Combination of Irreversible Electroporation with Sustained Release of a 
Synthetic Membranolytic Polymer for Enhanced Cancer Cell Killing 
5.1 Introduction 
Electroporation is the process of delivering a series of short electrical pulses to create 
tiny defects or “pores” within a cell membrane. If theses pores are transient and the cell 
membrane is able to recover, the process is referred to as reversible electroporation (RE). 
On the other hand, irreversible electroporation (IRE) involves the use of high-voltage 
short electrical pulses to create permanent pores within a cell membrane, leading to cell 
death by membrane lysis or loss of homeostasis [46].While a common goal of RE is to 
increase the uptake of membrane-impermeable entities while minimizing cell injury 
[142], Davalos et al in 2005 proposed to use IRE as a way to kill cancer cells [143].  
IRE is used clinically as a focal therapy to ablate tumors in the prostate, liver, 
pancreas, and kidneys [47,53,54]. In contrast to thermal ablation modalities that rely on 
extreme heating or cooling [50], IRE can be applied safely near large blood vessels or 
vital tissue structures [51]. It also spares the extracellular matrix, allowing for faster 
healing of healthy tissue while minimizing scarring [52].  Despite many advantages, IRE 
is usually considered a “last resort” for patients who do not respond to, or are not 
candidates for, other therapies [57]. A critical disadvantage of IRE is the inability to 
ablate large tumors (e.g. >3 cm in diameter) with an electric field strength that is safe to 
the patient [58]. IRE relies on two or more needle electrodes to deliver electric pulses. 
When the electric field intensity decreases sharply with the distance from an electrode 
[59] to the point below the effective threshold for IRE (500–1000 V/cm, depending on 
the cell type [46]), the cancer cells will only undergo RE and remain viable, resulting in 
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incomplete tumor ablation [60]. While it is possible to increase the ablation volume by 
applying high voltages, doing so carries the risk of damaging adjacent healthy tissue 
[61,62] and generate excessive heat near the electrodes due to Joule heating [63]. 
Repeated IRE treatments can be performed, attempting to fully ablate a tumor, but this is 
impractical under most clinical settings [47,54].  
Lowering the electric field threshold for cancer cell killing is an appealing approach 
to achieving large tumor ablation volume without using dangerously high voltage. 
Numerous reports show that cells treated with cationic molecules (such as procaine, 
tetracaine, lidocaine, and polyarginine), sodium dodecyl sulfate (SDS, a small-molecule 
surfactant) and dimethyl sulfoxide (DMSO, a polar aprotic solvent) can be killed by IRE 
at moderate electric field strengths [46,58,64–66]. The explanation of this effect is that 
the cations interact electrostatically with the anionic cell membrane, making it easier for 
IRE-induced pores to form [64,66], whereas surfactants and DMSO interact with 
membrane lipids to alter the membrane’s edge line and surface tension, making it more 
difficult for pores to reseal [58]. It is important to note that with the exception of 
polyarginine, none of these IRE sensitizers are cytotoxic themselves.  
Certain cationic peptides and synthetic polymers show membranolytic activity 
towards mammalian cells and are being investigated as anticancer agents 
[11,129,133,138]. Synthetic polymers may have advantages over peptides due to their 
chemical and biological stability, flexibility in structure, and the ease of synthesis on a 
large scale [11,133]. However, to our knowledge, combining synthetic membranolytic 
polymers with IRE for cancer treatment has not been attempted. Here we postulate that 
one such polymer, poly(6-aminohexyl methacrylate) (PAHM), will not only serve as an 
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IRE sensitizer by lowering the electric field threshold, but also synergizes with IRE to 
achieve greater cell killing due to its own cytotoxicity through membrane lysis (Figure 
5.1). We further recognize the need for localized and sustained delivery of PAHM to 
maximize cancer cell killing while avoiding damage to healthy cells. To this end, we set 
out to develop a method of sustained release of PAHM from the surface of polymer 
microspheres (Figure 5.1), which are already widely used clinically as embolic agents to 
treat local solid tumors [144]. In this paper, the killing of human pancreatic cancer cells 
by IRE and the membranolytic PAHM, applied separately or in combination, was 
evaluated. Embolic microspheres coated with PAHM were prepared and the release of 
PAHM was demonstrated. Finally, the combined effect of cancer cell killing by IRE and 
PAHM delivered by the embolic microspheres was analyzed. 
 
Figure 5.1 Schematic illustration of the combined killing of cancer cells by a synthetic 
membranolytic polymer (PAHM) and IRE. PAHM is coated onto embolic microspheres 
and then released to interact with cell membrane and sensitize the cells to IRE-induced 
























5.2 Materials and Methods 
5.2.1 Chemicals and reagents 
Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), 
Penicillin-Streptomycin (10,000 U/mL; 10,000 µg/mL), Dulbecco’s phosphate buffered 
saline (DPBS), phosphate buffered saline (PBS, pH 7.4), trypsin-EDTA (0.25%), trypan 
blue (0.4% solution, 0.85% NaCl), MTT (3-(4,5-dimethylthiazol- 2-yl)-2,5-
diphenyltetrazolium bromide) (MTT), dimethyl sulfoxide (DMSO), ethanol (200 proof), 
Alexa Fluor 488 NHS Ester, sodium bicarbonate, and N,N-dimethylformamide (DMF) 
were purchased from Thermo Fisher Scientific (Waltham, MA). Hydroxlamine 
hydrochloride and PD-10 desalting columns (Sephadex G-25 medium; exclusion limit: 
Mr 5000) were purchased from Millipore Sigma (Burlington, MA). Electroporation 
cuvettes (4 mm gap) were from Harvard Apparatus (Holliston, MA). UV transparent 
cuvettes (semi-micro, 1.5 mL) were purchased from USA Scientific (Ocala, FL).   
5.2.2 Synthesis of poly (6-amino-1-hexyl methacrylate) (PAHM) 
N-(tert-butoxycarbonyl) aminohexyl methacrylate (tBocAHM) was synthesized as 
described by Zhu et al [136]. PAHM was synthesized via atom transfer radical 
polymerization (ATRP) of tBocAHM followed by deprotection of the tBoc side chains 
based on a method reported by Ji et al [137]. The polymer was characterized using 1H 
NMR and gel permeation chromatography (GPC) as described by Ji [138]. The PAHM 
used in the subsequent experiments had a number-average molecular weight (Mn) of 2.08 
× 104, Dispersity (Đ) of 1.26, and average degree of polymerization (DP) of 100.  
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5.2.3 Fluorescence labeling of PAHM 
PAHM was fluorescently labeled with the NHS ester of Alexa Fluor 488 dye (lex/lem: 
494/517 nm; extinction coefficient = 71,000 cm-1M-1) according to manufacturer’s 
protocol. Briefly, PAHM was dissolved in sodium bicarbonate buffer (0.1 M, pH 8.3) to a 
concentration of 10 mg/mL. Alexa Fluor 488 was dissolved in DMF to a concentration of 
10 mg/mL. In a 1.8 mL amber glass vial, 100 µL Alexa Fluor 488 solution (10 mg/mL) 
was slowly added to 1 mL PAHM solution (10 mg/mL). Reaction was carried out for 1 h 
at room temperature (protected from light) with continuous stirring. Reaction was 
terminated by adding 100 µL hydroxylamine hydrocholoride solution (1.5 M, pH 8.5), 
followed by stirring for 1 h at room temperature. Theoretical degree of labelling was 1% 
based on feed ratio and 25-33% labelling efficiency (per manufacturer). Unreacted dye 
was removed by gel filtration with a PD-10 desalting column (Sephadex G-25 medium; 
exclusion limit: Mr 5000) equilibrated with deionized water. The purified fluorescently 
labeled PAHM solution was frozen at -80º C overnight and lyophilized under 0.020 mBar 
for 4 days in a FreeZone ® Freeze Dry System (Labconco, Kansas City, MO) equipped 
with a Maxima™ C Plus Vacuum Pump (Model M8c, Themo Fisher Scientific, 
Waltham, MA). Dried polymer was stored in a vacuum desiccator at room temperature 
(protected from light) until use. 
5.2.4 Optimizing method of coating embolic microspheres with PAHM 
PMMA microspheres with average diameter 71 µm or 100 µm were provided by 
Boston Scientific Corporation (Maple Grove, MN). PMMA microspheres were coated 
with PAHM by a solvent evaporation method. A mixture of fluorescently labeled and 
unlabeled PAHM (1:8 ratio of labeled:unlabeled) was dissolved in ethanol at total 
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concentration of 0.1 mg/mL or 0.5 mg/mL. In 2 dram glass vials, 1 mL PAHM solution 
was added to 50 mg PMMA microspheres (100 µm in diameter). Vials were placed 
uncovered on a slowly rotating orbital shaker (Lab-Line Instruments, Melrose Park, IL) at 
room temperature for 3 days to evaporate the ethanol. Based off the feed ratio, after 
drying the microspheres were coated with PAHM at a concentration of 2 µg/mg or 10 
µg/mg (µg PAHM/mg PMMA). Coated microspheres were stored in a vacuum desiccator 
(Bel-Art™ Space Saver Vacuum Desiccator 140 mm, Thermo Fisher Scientific, 
Waltham, MA) until use. 
To optimize and speed up the coating process, PMMA microspheres were coated with 
PAHM by three different solvent evaporation methods. A mixture of fluorescently 
labeled and unlabeled PAHM (1:8 ratio of labeled:unlabeled) was dissolved in ethanol at 
total concentration of 0.8 mg/mL. In 2 dram glass vials, 0.5 mL PAHM solution was 
added to 100 mg PMMA microspheres (100 µm in diameter). For coating method 1, 
ethanol was evaporated as described above (3 days on a slowly rotating orbital shaker). 
For coating method 2, uncovered vials were placed within a vacuum desiccator on top of 
a slowly rotating orbital shaker for 12 h. For coating method 3, ethanol was evaporated 
with compressed air for 10 min. The glass vials were covered with rubber septa with two 
puncture holes. A glass Pasteur pipette was pushed through the inlet hole to deliver the 
compressed air and a needle (21 gauge, 1” length) was pushed through the outlet hole to 
avoid pressure buildup and allow evaporated ethanol to escape. The compressed air-dried 
microspheres were then stored overnight in an isotemp vacuum oven (Model 280A, 
Thermo Fisher Scientific, Waltham, MA) connected to vacuum pump (Maxima D2A 
Rotary Vane Dual Stage Vacuum Pump, Thermo Fisher Scientific, Waltham, MA) to 
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evaporate any residual ethanol (room temperature, -29 inHg). Coated microspheres were 
stored in a vacuum desiccator (Bel-Art™ Space Saver Vacuum Desiccator 140 mm, 
Thermo Fisher Scientific, Waltham, MA) until use. 
To visualize the PAHM coating, coated microspheres were placed on glass slides. 
Fluorescent and bright-field images of the coated microspheres were acquired with an 
Olympus IX70 inverted fluorescence microscope equipped with an Olympus DP72 
camera and X-Cite 120 Wide-Field Fluorescence Microscope Excitation Light Source 
(Excelitas Technologies, Waltham, MA). Fluorescently labeled PAHM was visualized 
using an excitation wavelength of 480 ± 50 nm and emission wavelength of 535 ± 50 nm. 
An exposure time of 10 ms was selected for image capture to minimize microsphere 
autofluorescence. The fluorescence intensity of the PAHM on individual coated 
microspheres was quantified using ImageJ. 
All subsequent experiments (PAHM release kinetics and cytotoxicity assays) used 
microspheres coated with unlabeled PAHM at concentration of 10 µg/mg (µg PAHM/mg 
PMMA). PAHM was dissolved in ethanol at a concentration of 1 mg/mL. In 4 mL glass 
vials, 1 mL PAHM solution was added to 100 mg microspheres (71 µm or 100 µm). 
Ethanol was evaporated using method 1 as described above. Coated microspheres were 
stored in a vacuum desiccator (Bel-Art™ Space Saver Vacuum Desiccator 140 mm, 
Thermo Fisher Scientific, Waltham, MA) until use. 
5.2.5 In vitro release kinetics from coated microspheres 
The release of PAHM from coated microspheres was examined by suspending 25 mg 
coated microspheres (71 µm or 100 µm in diameter) in 1 mL release medium (cell culture 
medium without phenol red) in 12-well plates. The coated microspheres were incubated 
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in a humidified environment at 37ºC with 5% CO2 for 1 week. At particular time points, 
750 µL of the supernatant was sampled and replaced with fresh release medium. The 
sampled supernatants were then diluted with 0.75 mL release medium (final volume: 1.5 
mL) in UV transparent cuvettes. The amount of PAHM in the supernatant was measured 
by measuring absorbance at 245 nm using a Cary 100 UV-Vis Spectrophotometer 
(Agilent Technologies, Santa Clara, CA). Release kinetic profiles were expressed as the 
cumulative percentage released over time. 
5.2.6 Cell culture 
Human pancreatic adenocarcinoma cell line AsPC-1 were obtained from ATCC. 
AsPC-1 cells were cultured in a medium consisting of RPMI 1640 medium with 2 g/L 
glucose, 2 mM L-glutamine, 2 g/L sodium bicarbonate, 10% heat inactivated fetal bovine 
serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin. AsPC-1 cells were 
cultured in tissue culture flasks and incubated in a humidified environment at 37ºC with 
5% CO2. When cells reached ~80% confluency the culture medium was removed, cells 
were rinsed with DPBS, and 0.25% trypsin-EDTA was added for 5 min to detach cells 
from the flasks. Detached cells were split 1:3 to 1:6 to continue culture or used 
immediately for cytotoxicity experiments. 
5.2.7 Cytotoxicity of IRE in combination with free PAHM or PAHM released from coated 
microspheres 
Harvested cells were centrifuged at 200 x g for 5 min and supernatant was discarded. 
Cell pellets were resuspended in cell culture medium (without phenol red) and a 100 µL 
aliquot was stained 1:1 with trypan blue 0.4% solution and counted using a 
hemocytometer (Sigma-Aldrich, St. Louis, MO) and inverted microscope (Thermo Fisher 
 110 
Scientific, Waltham, MA). Cell suspensions were diluted to density of 675,000 cells/mL 
in culture medium (without phenol red) and 1 mL aliquots were dispensed into 2 mL 
microcentrifuge tubes.  
Free PAHM was dissolved in cell culture medium (without phenol red) to an initial 
concentration of 250 µg/mL and diluted to varying concentrations. To the 1 mL cell 
suspensions, 0.5 mL PAHM dilutions were added to give final concentrations of 0 – 50 
µg/mL. Coated microspheres (71 or 100 µm in diameter) were suspended in cell culture 
medium (without phenol red) to an initial concentration of 25 mg/mL and diluted to 
varying concentrations. To the 1 mL cell suspensions, 0.5 mL coated microsphere 
dilutions were added to give final concentrations of 0 – 5 mg/mL (corresponding to of 0 – 
50 µg/mL microsphere-coated PAHM).  
After 15 min incubation, cells were treated with IRE as described previously [145]. 
Briefly, 400 µL prepared cell suspension was pipetted into an electroporation cuvette 
(BTX 45-0126, Harvard Apparatus, Holliston, MA) between the two aluminum plate 
electrodes (4 mm apart). The cuvette was placed in an external electric field created by an 
electric pulse generator (BTX ECM Square Wave Electroporation System, BTX Model 
No. 830, Harvard Apparatus, Holliston, MA) which delivered 50 electrical pulses (100 µs 
pulse duration, 1 Hz frequency) at 150, 225, 300, 375, or 450 V (corresponding to electric 
field strengths of 375, 562.5, 750, 937.5, or 1125 V/cm). 
For 15 min exposure time samples, 400 µL treated cell suspensions were pipetted into 
2 mL microcentrifuge tubes. Cells suspensions were centrifuged at 185 x g for 5 min and 
supernatants were discarded. PAHM was washed away from cells with 1 mL DPBS 
(twice). Cell pellets were resuspended in 1 mL cell culture medium (without phenol red) 
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and plated in 12-well plates (180,000 cells/well). For 4 h and 24 h exposure time samples, 
400 µL treated cell suspensions were plated into 12-well plates (180,000 cells/well) and 
600 µL free PAHM or coated microsphere dilutions were added to maintain free PAHM 
or microsphere-coated PAHM concentrations of 0 – 50 µg/mL. After 4 h or 24 h 
incubation in a humidified environment at 37ºC with 5% CO2 cells were washed with 1 
mL DPBS (twice) and given 1 mL fresh cell culture medium (without phenol red).  
Cell viability was evaluated using an MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay [122]. For all exposure time samples, 100 µL MTT 
solution (5 mg/mL in DPBS) was added to each well. After 4 h incubation in a 
humidified environment at 37ºC with 5% CO2, 850 µL medium was removed from each 
well. Formazan crystals were dissolved in 1 mL DMSO and absorbance was measured at 
540 nm using a BioTek Cytation 3 Cell Imaging Multi-Mode Reader (BioTek 
Instruments, Winooski, VT). Cell viability was determined by normalizing by the 
absorbance of untreated cells (with the same exposure time). 
5.2.8 COMPUSYN modeling of drug synergy 
For each combination of IRE and free PAHM or IRE and PAHM released from 
coated microspheres, the combination index (CI) and dose reduction index (DRI) were 
calculated by the Chou-Talalay method with the CompuSyn software program 
(ComboSyn Inc., Paramus, NJ) [135]. Input parameters were the dose of each treatment 
(alone or in combination) and the corresponding fractional affect (Fa) – the fraction of 
cell growth inhibited by a particular dose, calculated as Fa = (100% - cell viability / 
100%). The dose-effect relationship for IRE, free PAHM, or PAHM released from coated 
microspheres and their combinations are described by the Median-Effect Equation Fa/Fu 
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= (D/Dm)m, where Fu is the unaffected fraction of cell growth (Fu = 1 – Fa), D is the dose 
required to produce Fa, Dm is the median-effect dose (i.e. IC50), and m is the dynamic 
order of the curve. Using these parameters, the CI and DRI can be calculated. The CI 
value is dimensionless quantification of drug interaction, calculated as CI = (D)1/(Dx)1 + 
(D)2/(Dx)2, where (Dx)1 is the dose of single drug D1 (i.e. IRE electric field strength) 
“alone” that inhibits cell growth by x%, (Dx)2 is the dose of a second drug D2 (i.e. PAHM 
concentration) “alone” that inhibits cell growth by x%, and (D)1 and (D)2 are the doses 
“in combination” that also inhibit cell growth by x%. CI = 1 indicates an additive effect; 
CI < 1 indicates a synergistic effect; CI > 1 indicates an antagonistic effect. The DRI is a 
measure of how much the dose of each drug can be reduced if used in combination at a 
given Fa as compared to the dose of each drug alone, calculated as (DRI)1 = (Dx)1/(D)1 
and (DRI)2 = (Dx)2/(D)2. DRI = 1 indicates no dose reduction; DRI > 1 indicates 
favorable dose reduction, DRI < 1 indicates unfavorable dose reduction.  
5.2.9 Statistical analysis 
ANOVA and Tukey HSD test for multiple comparisons were used to determine the 
significance of difference in cell viability between different treatment groups. ANOVA 
and Tukey HSD test for multiple comparisons were used to determine the significance of 
difference in fluorescence intensity of PAHM on coated microspheres. PAHM release 
profiles were fit with a two-phase exponential association model. All analyses were 




5.3.1 Tumor cell killing by IRE and PAHM applied individually 
Human pancreatic cancer cells (AsPC-1) were exposed to various doses of IRE or 
PAHM and cell viability was determined at various time points. As expected, higher 
electric field strengths led to lower cell viability (Figure 5.2A). For cells exposed to 750 
V/cm and below, over 70% of the cells remained viable. Even the highest electric field 
strength (1125 V/cm) only killed 68% of cells after 24 h. In comparison, PAHM had a 
more potent dose-dependent cell killing effect (Figure 5.2B). Greater than 85% of cells 
were killed when exposed continuously to ≥25 µg/mL of PAHM for 24 h. With 40 or 50 
µg/mL of PAHM 100% of the cells were dead after 24 h. Incubating the cells for 24 h 
after IRE treatment had no influence on cell viability with the exception of 1125 V/cm, 
which caused more cell death at 24 h than 4 h (Figure 5.2A). In contrast, cell killing by 
PAHM increased with exposure time (Fig. 2B). Interestingly, treating cells with PAHM 
for 4 h appears to result in lower cell viability than treating cells for 24 h. At PAHM 
doses ≤20 µg/mL, there was a significant reduction in cell viability after 4 h of exposure, 
but the cells appeared to recover after 24 h. However, at PAHM doses ≥25 µg/mL, this 
recovery did not occur, as there was no statistically significant difference in cell viability 




Figure 5.2 Cell viability after (A) IRE or (B) PAHM treatment applied separately. Data 
are shown as mean ± SD (A) (n = 4 – 6) (B) (n = 9 – 13). ANOVA with Tukey HSD test 
(* p <0.05, ** p <0.01, *** p<0.001, **** p<0.0001). 
5.3.2 Enhanced tumor cell killing by IRE/PAHM combinations 
To evaluate the ability of PAHM to enhance the cell killing effect by IRE, two 
electric field strengths of IRE were combined with three PAHM doses and cell viability 
was assessed at various time points (Figure 5.3A – C). For all exposure times, combining 
PAHM with IRE resulted in significantly more cell death. For example, while IRE 
treatment at 562.5 V/cm alone did not result in any appropriable cell death (95% 
viability), subsequent exposure to non-lethal doses of 5, 15, and 25 µg/mL of PAHM for 
15 min reduced cell viability to 64%, 48%, and 33%, respectively (Figure 5.3A). The 
trend remained constant and was more pronounced with 4 and 24 h of exposure to PAHM 
(Figure 5.3B). Notably, despite cell recovery after 24 h, combined treatment of IRE at 
562.5 V/cm and non-lethal doses of PAHM (5, 15, and 25 µg/mL) reduced cell viability 
to 72%, 17%, and 3%, respectively (Figure 5.3C). Similar effect was observed with IRE 
at the higher 912.5 V/cm (Figure 5.3A – C). 























































Figure 5.3 Cell viability after IRE treatment combined with PAHM exposure for (A) 15 
min (B) 4 h (C) 24 h. Data are shown as mean ± SD (n = 3 - 12). ANOVA with Tukey 
HSD test (* p <0.05, ** p <0.01, *** p<0.001, **** p<0.0001). (D) Combination index 
analysis (CI <1, = 0.9 - 1 (dashed lines), >1 indicates synergism, nearly additive effect, 
and antagonism, respectively). Dose reduction index analysis for (E) IRE and (F) PAHM 
(DRI <1, =1 (dashed line), >1 indicates unfavorable dose reduction, no dose reduction, 
and favorable dose reduction, respectively). 
5.3.3 PAHM sensitizes tumor cells for destruction by low-dose IRE 
To further examine the enhancement of IRE by PAHM, the Combination Index (CI) 
and Dose Reduction Index (DRI) for each IRE/PAHM combination were calculated by 
the Chou-Talalay method [135]. The CI is plotted against the fractional affect (Fa), the 
fraction of cell growth inhibited by a particular combination of IRE and PAHM (Figure 
5.3D). For 15 min PAHM exposure, the combination of IRE and PAHM appears to be 
slightly antagonistic as a majority of the CI are greater than 1.12. At longer PAHM 
exposure, the CI tends to decrease at higher Fa. For 4 h PAHM exposure, the 















































































































exposure, combinations with lower Fa displayed slight to moderate antagonism; however, 
combinations with higher Fa are nearly additive or display moderate synergy. The DRI of 
IRE tends to increase with Fa for all three exposure times and all DRI are greater than 1 
(Figure 5.3E). This indicates that for any combination with PAHM, a lower electric field 
strength can kill an equivalent fraction of cells as a higher electric field strength alone. 
The DRI of PAHM for all but one combination are greater than 1 (Figure 5.3F), 
indicating the PAHM dose can also be reduced when used in combination. For 15 min 
and 24 h exposure the DRI tends to decrease with Fa; however, the DRI tends to increase 
with Fa for 4 h exposure to PAHM. 
5.3.4 Coating PAHM onto embolic microspheres 
Embolic PMMA microspheres (100 µm in diameter) were coated with fluorescently 
labeled PAHM by a solvent evaporation method. Representative fluorescent micrographs 
(Figure 5.4A) show that increasing the concentration of PAHM resulted in a thicker 
coating as microspheres coated with 10 µg PAHM/mg PMMA showed 10.5-fold brighter 




Figure 5.4 Characterization of embolic microspheres coated with fluorescently labeled 
PAHM. (A) Representative fluorescence microscopy images of microspheres coated with 
different amounts of PAHM (µg PAHM/mg PMMA). (B) Fluorescence intensity of 
PAHM coating on individual microspheres. (C) Representative fluorescence microscopy 
images of microspheres coated with PAHM by different solvent evaporation methods. 
(D) Fluorescence intensity of PAHM on individual microspheres after coating by 
different methods. Data are shown as mean ± SD (A) (n = 16 – 63) (B) (n = 165 – 186). 
ANOVA with Tukey HSD test (* p <0.05, ** p <0.01, *** p<0.001, **** p<0.0001). 
To optimize the coating process, embolic microspheres were coated with 4 µg 
PAHM/mg PMMA fluorescently labeled PAHM by three different solvent evaporation 
methods. Representative fluorescent micrographs of microspheres after coating are 
shown in Figure 5.4C and quantification of the fluorescence intensity is shown in Figure 
5.4D. In method 1, ethanol was quickly evaporated within 10 min which resulted in a 
bright, relatively uniform coating (Figure 5.4C). In method 2, the slower evaporation of 
ethanol over 12 h seemed to slightly increase the amount of PAHM coated on the 
microspheres, as indicated by the 1.2-fold brighter fluorescence as compared to method 1 
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(Figure 5.4D). However, further slowing the evaporation to 3 days (method 3) resulted in 
a much dimmer coating (Figure 5.4C,D). We chose to use method 1 to coat microspheres 
for all subsequent experiments because it was fast while still generating a good coating. 
5.3.5 Sustained release of PAHM from microspheres 
Microspheres (71 µm or 100 µm in diameter) coated with 10 µg PAHM/mg PMMA 
were submerged in cell culture medium to evaluate the release kinetics of coated PAHM 
(Figure 5.5). PAHM release was quantified by UV-Vis absorption (Figure 5.6). PAHM 
was released slightly faster from 71 µm PMMA microspheres than 100 µm. After an 
initial burst within the first 4 h, 69% and 59% of coated PAHM was released from 71 µm 
and 100 µm PMMA microspheres. Subsequently a sustained release of over 20% of 
coated PAHM continued over the course of 1 week (between days 2 and 7).  
 
Figure 5.5 Release kinetics of PAHM from coated embolic microspheres in cell culture 
medium at 37ºC. Data are shown as mean ± SD (n = 4) and are fit with a two-phase 
exponential association model. 



































Figure 5.6 Quantification of PAHM in cell culture medium. (A) UV-Vis absorption 
spectra of aqueous PAHM solution of various polymer concentrations. (B) Standard 
curve showing absorbance at 245 nm vs. PAHM concentration. 
5.3.6 Tumor cell killing by PAHM released from microspheres 
The viability of AsPC-1 cells after exposure to microspheres coated with 10 µg 
PAHM/mg PMMA is shown in Figure 5.7. PMMA microspheres alone show little to no 
toxicity (Figure 5.8). Similar to free PAHM, the exposure time to PAHM released from 
71 µm microspheres had a significant effect on cell viability (Figure 5.7A). Fifteen 
minutes of exposure to the highest dose (50 µg/mL) of microsphere-coated PAHM killed 
47% of cells. Exposure for 4 h, however, greatly reduced cell viability – less than 13% of 
the cells were alive after treatment with ≥20 µg/mL microsphere-coated PAHM. The 
cells recovered much of their viability after 24 h, thus only the highest dose (50 µg/mL) 
of microsphere-coated PAHM achieved more cell killing than at shorter time frames. 
Similar dose-dependent cell killing was observed for 100 µm microspheres, although the 
time dependence of killing was not as prominent as compared to 71 µm microspheres 
(Figure 5.7B).  
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Figure 5.7 Cell viability after exposure to PAHM released from coated embolic 
microspheres with average diameter (A) 71 µm (B) 100 µm. Data are shown as mean ± 
SD (n = 6 – 12), ANOVA with Tukey HSD test (* p <0.05, ** p <0.01, *** p<0.001, 
**** p<0.0001). 
 
Figure 5.8 Cell viability after exposure to uncoated embolic microspheres. Mean are 
shown as mean ± SD (n = 2). 
5.3.7 Time and dose-dependence of cell killing by combination of PAHM-coated 
microspheres and IRE 
Due to the slower release of PAHM and the much smaller differences in cell viability 
between 4 h and 24 h exposure times, 100 µm microspheres were chosen over 71 µm 
ones to examine the ability of PAHM-coated microspheres to enhance IRE (Figure 5.9). 
Released PAHM did enhance the cell killing effect of IRE after 15 min and especially 4 
h, but did not achieve significant enhancement after 24 h. For 15 min exposure, the 
viability of cells exposed to 912.5 V/cm decreased from 95% down to 40 – 54% when 
coated microspheres were added; however, there were no statistically significant 























































































differences among the three microsphere doses (Figure 5.9A). The most substantial IRE 
enhancement was seen at 4 h exposure to PAHM-coated microspheres, as the viability of 
cells exposed to 562.5 V/cm was reduced from 86% to 65%, 56%, and 19% for 5 µg/mL, 
15 µg/mL, and 25 µg/mL microsphere-coated PAHM (Figure 5.9B). This enhancement 
largely disappeared after 24 h exposure with the exception of combining 562.5 V/cm of 
IRE and 25 µg/mL of PAHM, which reduced cell viability to 75% from 91% by IRE 
alone (Figure 5.9C).  
 
Figure 5.9 Cell viability after IRE treatment combined with exposure to PAHM released 
from coated embolic microspheres for (A) 15 min (B) 4 h (C) 24 h. Data are shown as 
mean ± SD (n = 3 – 9). ANOVA with Tukey HSD test (* p <0.05, ** p <0.01, *** 
p<0.001, **** p<0.0001). (D) Combination index analysis (CI <1, = 0.9 – 1 (dashed 
lines), >1 indicates synergism, nearly additive effect, and antagonism, respectively). Dose 
reduction index analysis for (E) IRE and (F) microsphere-coated PAHM (DRI <1, =1 
(dashed line), >1 indicates unfavorable dose reduction, no dose reduction, and favorable 

















































































































5.3.8 Dose reduction by combining PAHM-coated microspheres with IRE 
Calculation of CI shows that combining IRE with exposure to PAHM-coated 
microspheres for 15 min is antagonistic at low Fa, but the combination becomes 
synergistic at intermediate Fa (Figure 5.9D). With 4 h exposure, most of the CI are within 
(or close to) the 0.9 – 1.1 range which indicates a nearly additive effect. All combinations 
with 24 h exposure displayed CI greater than 1.1. At low Fa the combinations are 
antagonistic but tend to become additive or synergistic at medium and high Fa. The DRI 
for IRE tend to increase with Fa and for Fa >0.1, the DRI for IRE is greater than 1 for all 
three exposure times (Figure 5.9E). The DRI for microsphere-coated PAHM also trends 
upward with Fa with values greater than 1 for Fa >0.2 (Figure 5.9F). 
5.4 Discussion 
One proposed mechanism to explain the physicochemical basis of electroporation is 
the nucleation theory, where a transmembrane potential can reduce the energy barrier for 
critical pore formation in the membrane. The probability of critical pore formation is 
related to membrane physical properties such as surface tension, edge line tension, and 
transmembrane voltage [146]. The application of pulsed electric fields during 
electroporation raises the transmembrane potential to overcome the energy barrier. 
Initially a hydrophobic pore forms in the membrane but if the pore radius exceeds a 
critical size (0.3 to 0.5 nm) it transitions into a hydrophilic one, allowing water to rush 
into the cell. Pore formation does not always induce cell death. When low electric field 
strengths are applied, as is the case during RE, cells are able to repair the cell membrane 
[47]. In contrast, when high electric field strengths are applied during IRE, cells are 
unable to repair the membrane and die due to various consequences, such as rupture from 
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osmotic stress, loss of critical organelles, or influx of cytotoxic molecules [46]. While 
IRE has been used to ablate tumors in a number of different organs, the tumor volume 
that can be treated is limited by the high electric field strength required to induce cancer 
cell death [58]. 
IRE will be much improved if the electric field threshold required to induce cell death 
can be lowered. One way to achieve this is by sensitizing the cell membrane to make it 
more susceptible to IRE [60]. SDS (a surfactant) and DMSO (a nonpolar protic solvent) 
can interact with membrane lipids to alter the membrane’s edge line tension and surface 
tension, which inhibits the resealing of pores formed by electroporation, thereby 
enhancing the efficacy of IRE [46,58]. Cations can interact with the negatively charged 
cell membrane and enhance the transmembrane potential locally, lowering the electric 
field intensity required to induce cell death by IRE. A number of cations have also been 
shown to enhance IRE, including cationic anesthetics (such as procaine, tetracaine, and 
lidocaine [64,65]) and a cationic peptide (polyarginine) [66]. Drugs that indirectly alter 
the transmembrane potential have also been shown to enhance IRE [147,148]. 
In this study, we have shown that a synthetic membranolytic polymer, PAHM, can 
enhance the ability of IRE to kill human pancreatic cancer cells, and that combining IRE 
with PAHM reduces the doses of both IRE and PAHM needed for effecting cell killing 
(Figure 2 and 3). We speculate that the mechanism of PAHM sensitizing cell membranes 
to IRE resembles those of cations [64,66], surfactants and DMSO [58]. With cationic side 
chain, PAHM may electrostatically interact with anionic cell membrane to alter the 
transmembrane potential and make the membrane more susceptible to form pores at low 
electric field strengths [66]. Furthermore, the amphipathic properties of PAHM may 
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make it more difficult for the IRE-induced membrane pores to heal [58]. With the 
capacity of sensitizing tumor cells to low-field-strength IRE, increased volume of tumor 
ablation could potentially be achieved through combined use of PAHM and IRE. 
The effect of cell killing by low doses (≤20 µg/mL) of PAHM (alone and in 
combination with IRE) is dependent on the duration of treatment. Unexpectedly, cell 
viability measured by the MTT assay was higher at 24 h than 4 h despite continued 
exposure to PAHM or combination with IRE (Figure 5.2B, Figure 5.3A-C). The MTT 
assay measures cellular metabolic activity as a proxy for cell viability [149]. If the cell 
membrane damage due to low doses of PAHM is not too extensive, the cells will be able 
to repair the membrane, which can take tens of minutes. During this time the cells may 
become temporarily less metabolically active [149]. The leaking of ATP from the 
damaged cell membrane can further reduce cell metabolism [150]. These phenomena 
may account for the apparent higher degree of cell death at 4 h. After 24 h, cells that 
survive PAHM treatment will have likely recovered full metabolic activity. Interestingly, 
such time-dependence of cell viability was not observed for IRE treatment alone (Figure 
5.2A). The unique and disparate temporal dynamics of IRE and PAHM treatments can be 
exploited further (for example, continuous exposure of low-dose PAHM accompanied by 
multiple, properly timed pulses of IRE), in order to achieve even greater therapeutic 
benefit.  
A potential limitation of PAHM is its nonspecific cytotoxicity. To avoid systemic 
dissemination, PAHM was coated onto embolic microspheres to allow for targeted 
delivery to a tumor. Embolization is an established cancer therapy, in which local blood 
vessels are deliberately occluded to starve a tumor of its blood supply [144]. Embolic 
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agents can be delivered simultaneously with chemotherapeutics via catheters in a process 
known as transcatheter arterial chemoembolization (TACE), currently under preclinical 
investigation [151–153]. Analogous to TACE, our PAHM-coated microspheres could 
also be delivered via catheter infusion to occlude tumor blood vessels and concentrate the 
PAHM within the tumor. The PAHM would slowly elute from the coated microspheres to 
accumulate locally within a tumor to sensitize the cancer cells to IRE and directly killing 
them. We chose to use PMMA microspheres over other types of embolic agents, such as 
liquids or metallic coils [144], because conductive materials have been shown to distort 
the ablation zone during IRE [154]. PMMA microspheres can be produced with 
consistent and well-defined diameters, allowing them to embolize deep, distal 
microvasculature of the tumors [155]. Therefore, we envision a “triple threat” strategy, 
where tumors can be attacked by embolic microspheres, which also release cytotoxic 
PAHM, which kills tumor cells either directly or through sensitization of IRE. The 
mutual enhancement among different therapeutic modalities and the in vivo antitumor 
efficacy of this strategy will be the subject of future investigation. 
We developed a simple, effective method of coating PAHM onto PMMA 
microspheres by controlling the rate of solvent evaporation [156,157] (Figure 5.4). When 
submerged in cell culture medium, PAHM releases from coated microspheres over the 
course of 1 week (Figure 5.5). PAHM releases slightly faster from 71 µm microspheres 
than 100 µm microspheres, presumably due to the greater surface area of the smaller 
particles. An initial burst release of approximately 70% of the total PAHM is seen over 
the first day, followed by a more sustained release in the next 6 days. This release profile 
could be attractive in vivo, where a high dose of PAHM is initially delivered for effective 
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tumor cell killing followed by sustained release to sensitize any surviving cells for 
destruction by IRE.  
Microspheres coated with PAHM were capable of killing tumor cells, although the 
effect was less prominent than free PAHM at equivalent doses (Figure 5.7). This is 
expected because the sustained release profile dictates that only a fraction of PAHM was 
released from the microspheres at any given time (Figure 5.5). Similarly, the higher 
percentage of cell killing by 71 µm microspheres at 4 h compared with 100 µm 
microspheres can be explained by the higher amount of PAHM released from the smaller 
size microspheres over the course of 4 h. Despite the low-level gradual release of PAHM 
from microspheres, significant enhancement of the efficacy of IRE was observed at 15-
min and 4-h time points (Figure 5.9A,B). Judging by the CI values, the nature of the 
enhancement is either synergistic or additive over a wide range of cell death rates (Fa = 
0.3 ~ 1) (Figure 5.9D). More importantly, the DRI for nearly all treatment combinations 
are greater than 1 (Figure 5.9E,F). This suggests that lower doses of IRE/PAHM in 
combination have the same potency of killing cells as higher doses of the two modalities 
used separately. Dose reduction of IRE and/or PAHM may translate into clinical benefits 
including less toxic side effects, less cost and higher patient compliance.  
Some have argued that the chemical sensitizers for IRE should not be inherently 
cytotoxic [58,66]. However, due to the stochastic nature of IRE, even high electric fields 
do not guarantee complete cell death. Local electrical heterogeneity within the tumor 
tissue can leave patches of live cells within the ablation zone. These live patches are 
unique to IRE ablation and often lead to tumor recurrence [46,59]. By using a cytotoxic 
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sensitizer, PAHM, there is the possibility of eliminating these live patches for a more 
robust tumor ablation. 
 Certain IRE-related parameters, such as the number, duration, and frequency of 
pulses, can be optimized to improve the efficacy of IRE [46]; however, all IRE protocols 
would benefit from lowering the electric field threshold in the tumor tissue. IRE has also 
been shown to release tumor antigens [52,158–160], which can be damaged by high 
electric field strengths [161]. Using PAHM to lower the electric field strength used 
during IRE, it may be possible to preserve a greater percentage of tumor antigens in their 
native form and generate a more robust antitumor immune response. 
Taken together, our results suggest that a synthetic membranolytic polymer, PAHM, 
can be coated onto and released from embolic microspheres to reduce the electric field 
strength required for killing human pancreatic cancer cells by IRE. Future studies will 
focus on elucidating the mechanism of PAHM-modulated sensitization of cells to IRE. 
The timing, frequency, and duration of the treatment combinations could be optimized to 
achieve better cell killing. Efficacy of the combination therapy will need to be validated 
in appropriate in vivo tumor models.  
5.5 Conclusions 
We have demonstrated that a synthetic membranolytic polymer, PAHM, when 
combined with IRE, led to enhanced killing of human pancreatic cancer cells. We have 
further developed a simple process of coating PAHM onto embolic microspheres, which 
provided for sustained release of PAHM. Nearly all tested combinations of PAHM and 
IRE caused cancer cell death in a dose-sparing manner, and some combinations achieved 
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cell killing synergistically. These findings established that sustained release of PAHM 
from embolic microspheres have the potential to improve IRE-mediated tumor ablation. 
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Chapter 6 Conclusions and Future Directions 
6.1 Improving the Mucoadhesive Wafer Formulation 
Varying the ratio between CMC and ALG resulted in wafers with different 
microstructure, mechanical properties, disintegration time, and release kinetics of model 
compounds. Wafers with high CMC content were highly mucoadhesive to sublingual 
mucosal tissue and could withstand extensive washing, leading to improved protein 
permeation into the tissue. On the other hand, wafers with high ALG content were not 
only mechanically robust, but also able to protect a model enzyme (β-galactosidase) 
against lyophilization and heat challenge. HIV gp140 protein loaded in wafers of the 
optimal composition could be stored and transported without cold chain, while 
maintaining antigen-specific immunogenicity after sublingual vaccination in mice. These 
findings established that the CMC/ALG binary blend polymer wafers have the potential 
to improve the sublingual delivery and storage stability of protein-based vaccines. 
Although the current CMC/ALG binary blend has shown desirable properties, the 
wafer formulation could be improved. While wafers maintained the immunogenicity of 
the protein vaccine for ~2 weeks without cold chain storage, the long-term storage 
stability has not yet been investigated. To further enhance the preservation of the protein 
vaccines, additional stabilizers can be added to the wafer formulations. A number of 
chemicals have a history of use as protein-stabilizing compounds, including polyols (e.g., 
glycerol, mannitol, sorbitol), sugars (e.g., sucrose and trehalose), and amino acids (e.g., 
glycine, proline) [82]. One, or more, of these stabilizing compounds could be added to 
the wafer formulation to protect that protein vaccines. 
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Another opportunity for improvement is the co-encapsulation and controlled release 
of both antigen and immunostimulatory adjuvant using the same wafer formulation. For 
the sublingual immunization of mice with the current CMC/ALG binary blend, the 
adjuvant (αGalCer) had to be delivered separately in liquid solution. While αGalCer is 
soluble in DMSO, it is not soluble in water. While the current formulation method cannot 
load poorly soluble cargo into the wafers, αGalCer could be first encapsulated in 
amphiphilic liquid polymer nano-droplets and then loaded into the wafers. Our lab has 
previously designed a biodegradable amphiphilic liquid polymer composed of multiple 
short blocks of polyethylene glycol (PEG) and polycaprolactone (PCL) connected 
through acid-labile acetal linkages. This polymer forms self-emulsifying nano-droplets in 
water for delivering poorly soluble drugs [162]. Preliminary results have shown that these 
nano-droplets can be incorporated into the CMC/ALG binary blend polymer wafers. In 
addition to αGalCer, these nano-droplet loaded wafers are a promising material system 
for the encapsulation and delivery of other poorly soluble cargos to the sublingual 
mucosal. 
6.2 PVA Wafers for Sublingual Delivery and Stabilization of DNA Vaccines 
Polymer wafers were also effective delivery systems of PEI/DNA polyplexes for 
nonviral gene delivery. While wafers composed of CMC and ALG were ineffective 
polyplex carriers, due to their anionic charges disrupting the polyplex attraction to cell 
membranes, wafers composed of PVA greatly enhanced the in vitro transfection 
efficiency of polyplex-mediated gene delivery in 10% serum containing medium. The 
physical form of the PVA wafers was crucial for this enhancement. Like CMC, PVA also 
has mucoadhesive properties and has been used as an excipient for oral mucosal drug 
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delivery [84]. The polyplex-loaded PVA wafers may exceptionally suited for sublingual 
delivery of DNA vaccines. Sublingual delivery of PEI/DNA polyplexes, followed by a 
mucosal protein boost, have been shown to generate antigen-specific antibodies [163]. 
However, similar to protein vaccines, polyplexes are subject to saliva washout. 
Mucoadhesive PVA wafers could enhance permeation into the sublingual tissue and 
transfection efficiency of DNA vaccines. 
In addition to poor transfection efficiency in the presence of serum, poor storage 
stability of polyplexes limits their clinical practicability. Due to the tendency of 
polyplexes to aggregate in solution, freshly prepared formulations are required prior to 
administration [164]. While PEI/DNA polyplexes have been previously lyophilized, this 
is often associated with loss of activity [37]. Our PVA wafers may be able to stabilize the 
polyplexes during lyophilization and storage. Currently, polyplex-loaded PVA wafers are 
used to transfect NIH/3T3 cells within 1 day of preparation. However, preliminary results 
indicate that even after storage for 2 weeks at room temperature without desiccation, the 
polyplex-loaded PVA wafers could still transfect cells.  Although the mechanisms of 
polyplex stabilization are not fully understood [164], the PVA wafers may be able to 
stabilize polyplexes similar to the CMC/ALG wafer protection of protein vaccines. 
6.3 Optimizing Anticancer Therapy Combinations and Potential Immunological 
Implications 
The membranolytic synthetic polymer, PAHM, displayed high levels of cytotoxicity 
to multiple cancer cell cells. In addition, PAHM enhanced the cytotoxicity of other 
cancer therapies. The membrane disruption by PAHM led to increased cellular uptake of 
DOX. When used in combination, PAHM and DOX killed cancer cells synergistically. 
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This synergy allowed far lower DOX doses to be used for to kill cancer cells, which 
could potentially minimize negative side effects. We also demonstrated that PAHM 
enhances the cytotoxicity of IRE. The combination of PAHM and IRE allowed the use of 
lower electric field strengths to kill cancer cells, which could potentially improve IRE-
mediated tumor ablation. PAHM was also coated onto embolic microspheres to provide 
for sustained release and targeted tumor delivery. While nearly all tested combinations of 
PAHM and DOX or PAHM and IRE killed cancer cells in a dose-sparing manner, 
treatment combinations could be optimized to achieve better cell killing. Like PAHM, 
IRE-induced membrane disruption could lead to increased cellular uptake of DOX. In 
addition, DOX could be loaded into an embolic carrier for target tumor delivery. How the 
hypoxia due to embolization effects the cytotoxicity of the treatment combinations is also 
yet to be explored. 
In addition to the immediate cytotoxicity, the ability of these treatment combinations 
to induce an anticancer immune response is another point of interest. IRE has been shown 
to release tumor antigens capable of stimulating an antitumor immunity. However, the 
use of adjuvant immunostimulants is often necessary to generate a robust immune 
response [52]. One explanation is IRE-induced cell death may not release sufficient 
damage-associated molecular patterns (DAMPs), danger signals that induce the 
maturation of dendritic cells that mediate anticancer immunity [165]. We have previously 
shown that cancer cells treated with PAHM release ATP and HMGB1, two such DAMPs 
[166]. PAHM-mediated membrane lysis is also expected to release tumor antigens. Thus, 
the combination of PAHM and IRE (or DOX) could not only effectively kill cancer cells 
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but could also release sufficient tumor antigens and DAMPs to induce a prolonged 
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